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Abstract  
Systemic glucose regulation is essential for human survival as low or chronically high 
glucose levels can be detrimental to the health of an individual. Glucose levels are highly 
regulated via inter-organ communication networks that alter metabolic function to 
maintain euglycemia. For example, when nutrient levels are low, pancreatic α-cells 
secrete glucagon, which signals to the liver to promote glycogen breakdown and glucose 
production. In times of excess nutrient intake, pancreatic β-cells release insulin. Insulin 
signals to the liver to suppress hepatic glucose production, and signals to the adipose 
tissue and the skeletal muscle to take up excess glucose via insulin-regulated glucose 
transporters. Defects in this inter-organ communication network including insulin 
resistance can result in glucose deregulation and ultimately the onset of type-2 diabetes 
(T2D).  
 
To identify novel regulators of insulin-mediated glucose transport, our laboratory 
performed an siRNA-mediated gene-silencing screen in cultured adipocytes and 
measured insulin-mediated glucose transport. Gene silencing of Mitogen-activated 
protein kinase kinase kinase kinase 4 (Map4k4), a Sterile-20-related serine/threonine 
protein kinase, enhanced insulin-stimulated glucose transport, suggesting Map4k4 
inhibits insulin action and glucose transport. Thus, for the first part of my thesis, I explore 
the role of Map4k4 in cultured adipose cells and show that Map4k4 also represses lipid 
synthesis independent of its effects on glucose transport. Map4k4 inhibits lipid synthesis 
in a Mechanistic target of rapamycin complex 1 (mTORC1)- and Sterol regulatory 
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element-binding transcription factor 1 (Srebp-1)-dependent mechanism and not via a c-
Jun NH2-terminal kinase (Jnk)-dependent mechanism. For the second part of my thesis, I 
explore the metabolic function of Map4k4 in vivo. Using mice with loxP sites flanking 
the Map4k4 allele and a ubiquitously expressed tamoxifen-activated Cre, we inducibly 
ablated Map4k4 expression in adult mice and found significant improvements in 
metabolic health indicated by improved fasting glucose and whole-body insulin action. 
To assess the role of Map4k4 in specific metabolic tissues responsible for systemic 
glucose regulation, we employed tissue-specific knockout mice to deplete Map4k4 in 
adipose tissue using an adiponectin-cre transgene, liver using an albumin-cre transgene, 
and skeletal muscle using a Myf5-cre transgene. Ablation of Map4k4 expression in 
adipose tissue or liver had no impact on whole body glucose homeostasis or insulin 
resistance. However, we surprisingly found that Map4k4 depletion in Myf5-positive 
tissues, which include skeletal muscles, largely recapitulates the metabolic phenotypes 
observed in systemic Map4k4 knockout mice, restoring obesity-induced glucose 
intolerance and insulin resistance. Furthermore these metabolic changes were associated 
with enhanced insulin signaling to Akt in the visceral adipose tissue, a tissue that is 
nearly devoid of Myf5-positive cells and does not display changes in Map4k4 expression. 
Thus, these results indicate that Map4k4 in Myf5-positive cells, most likely skeletal 
muscle cells, inhibits whole-body insulin action and these effects may be mediated via an 
indirect effect on the visceral adipose tissue. The results presented here provide evidence 
for Map4k4 as a potential therapeutic target for the treatment of insulin resistance and 
T2D.   
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CHAPTER I: INTRODUCTION 
Whole-body glucose homeostasis 
 
Controlled glucose homeostasis is essential for the survival of mammals (1). 
Hyperglycemia (elevated blood glucose) can result in ketoacidosis, neuropathy, 
nephropathy, and eye complications that can lead to blindness (1, 2).  Conversely, 
because neurons rely primarily on glucose as a fuel source, hypoglycemia (low blood 
glucose levels) can result in compromised brain function, coma, and death (3). Due to the 
dire consequences that occur if blood glucose is deregulated, blood glucose levels are 
maintained within a narrow range (approximately 5mM) by an elaborate physiological 
system that involves multi-organ communication and regulation in response to nutrient 
conditions and hormonal signals (2, 4).  
 
Appropriate glucose homeostasis is maintained primarily by the actions of glucagon and 
insulin, hormones that are released by the pancreas in response to nutritional status. 
These two hormones act on many organs including the liver, the adipose tissue, and the 
skeletal muscle to change cellular functions that aid in glucose control (2). In fasting 
conditions, circulating glucose levels decrease, stimulating pancreatic α-cells to release 
glucagon (5). Glucagon signals to the liver to produce glucose via breakdown of 
glycogen (glycogenolysis) and synthesis of glucose from pyruvate and other substrates 
(gluconeogenesis), thus restoring glucose levels (5).  In the post-prandial state, a glucose 
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surge that results from digestion of dietary sources including carbohydrates, promotes 
pancreatic β-cells to secrete insulin. Insulin promotes glucose uptake in the muscle and 
adipose tissue while suppressing hepatic glucose production (2). The net effect of insulin 
action on these three organs helps return blood glucose to basal levels. Thus, in healthy 
individuals, blood glucose concentrations are tightly regulated and maintained within a 
narrow range (approximately 5mM) despite variations in glucose utilization or 
availability of exogenous glucose. Failure to control circulating glucose levels results in 
diabetes, defined as displaying fasting glucose levels higher than 7mM and Hemoglobin 
A1C values higher than 6.5% (6). Type I diabetes is characterized by immune cells 
attacking and destroying β-cells, resulting in loss of insulin-secreting cells. Type II 
diabetes (T2D), on the other hand, is more common and a frequent complication of 
obesity that also results in gradual loss of insulin-secreting cells (7).  
 
Chronic over-nutrition and a sedentary lifestyle promote adipose tissue expansion, which 
results in obesity. Adipose tissue expansion promotes inflammation that compromises 
adipose tissue function, resulting in insulin resistance (8-10). Insulin resistance is 
manifested as reduced insulin-mediated glucose disposal and unrepressed hepatic glucose 
production, resulting in deregulation of blood glucose levels and hyperglycemia (11). To 
maintain glucose homeostasis, β-cells compensate by secreting more insulin (12, 13). 
Chronic obesity-induced insulin resistance can ultimately lead to β-cell failure (β-cell 
exhaustion and death), resulting in the onset of T2D (12, 14). Therefore, T2D is a 
condition with defects in both insulin secretion and insulin action.  
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T2D is predicted to affect approximately 9% of the population worldwide, and the 
number of afflicted individuals is projected to increase as the incidence for T2D-
predisposing conditions including obesity continue to rise (7). It is of paramount 
importance to therapeutically manage T2D, as this disease is commonly associated with 
other more costly and deadly co-morbidities including cancer, cardiovascular disease, 
retinopathy, and nephropathy (7). To that extent, to improve glycemic control, current 
therapies aim to increase insulin secretion or suppress hepatic glucose production; 
however, most patients inevitably require further intervention (15). Thiazolidinediones 
(TZDs) are potent insulin-sensitizing drugs that target Peroxisome Proliferator Activated 
Receptor (Pparγ) and address the underlying pathophysiology in T2D; however, these 
drugs are in limited use due to contra-indications, including cardiovascular side effects 
(16, 17). Thus, discovering novel proteins that can be targeted with drug therapies to 
improve peripheral insulin sensitivity would prove useful in the treatment for T2D. 
 
Insulin signaling pathway   
 
Insulin is an anabolic hormone that activates metabolic pathways to promote cellular 
growth. A post-prandial glucose surge induces β-cell insulin secretion into the 
bloodstream to reach peripheral target tissues where it binds to the α-subunits of the 
insulin receptor (InsR) (18). Binding of insulin to the InsR causes a conformational 
change that brings the β-InsR subunits in proximity, promoting autophosphorylation and 
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further increasing receptor kinase activity (Figure 1.1) (19, 20). The InsR is a unique 
receptor-tyrosine kinase, as it does not directly bind to downstream effectors; instead, 
InsR activation leads to rapid tyrosine phosphorylation and recruitment of scaffold 
proteins known as Insulin receptor substrate (Irs) proteins (21). Phosphorylated tyrosine 
residues on these Irs proteins, in turn, promote the recruitment and activation of 
Phosphatidylinositol-4,5-biphosphate 3-kinase (PI3K) (18). Enhanced PI3K activity 
results in the transient increase of phosphatidylinositol (3,4,5)-triphosphate (PIP3) in the 
plasma membrane (22). PIP3 binds to the pleckstrin homology (PH) domain of various 
proteins, including Protein kinase b (Pkb/Akt) and 3-Phosphoinositide-dependent protein 
kinase-1 (Pdk1), effectively recruiting these proteins to the plasma membrane (23). At the 
plasma membrane, Pdk1 and Mechanistic target of rapamycin complex 2 (mTORC2) 
phosphorylate Akt, resulting in maximal Akt activation (24). Insulin via Akt activation 
will then initiate signaling cascades that promote anabolic processes including cellular 
growth, glucose uptake, lipid metabolism, glycogenesis, and cell survival.  
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Figure 1.1 Canonical insulin signaling pathway. 
  
Figure 1.1 Canonical insulin signaling pathway. Binding of insulin to the insulin 
receptor (InsR) promotes InsR autophosphorylation and recruitment of Insulin Receptor 
Substrate (Irs) proteins. Tyrosine phosphorylated Irs proteins further recruit and 
promote the activation of Phosphatidylinositol-4,5-biphosphate 3-kinase (PI3K). 
Activated PI3K elevates Phosphatidylinositol (3,4,5)-triphosphate (PIP3) levels, 
recruiting Protein Kinase B (Akt) to the cell surface. At the cell surface, Akt is 
phosphorylated and activated by 3-Phosphoinositide-dependent protein kinase-1 (Pdk1) 
and Mechanistic Target of Rapamycin (mTORC2, also known as Pdk2). Activated Akt 
will then initiate a plethora of anabolic signaling pathways that protein synthesis, lipid 
synthesis, glucose transport and metabolism, glycogen synthesis, proliferation, and 
survival. 
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Insulin promotes glucose disposal via enhancement of the PI3K and Akt signaling 
pathway (25). Skeletal muscle and adipose tissue express Solute carrier family 2 
(facilitated glucose transporter) member 4 (Slc2a4 or Glut4), an insulin-responsive 
glucose transporter (26). Under basal conditions, Glut4 is concentrated in specialized 
intracellular vesicles (27). Insulin stimulation promotes Glut4 vesicle translocation and 
fusion with the plasma membrane, increasing the concentration of Glut4 on the cell 
surface by 10-15 fold, effectively allowing glucose to enter the cell to be metabolized 
(27). Whole-body Glut4 heterozygous mice (-/+) display a decrease in Glut4 expression 
in adipose tissue and muscle, resulting in hyperglycemia and hyperinsulinemia (28). 
Therefore, the ability of insulin to regulate glucose transport in the adipose and muscle is 
a critical mechanism in maintaining whole-body glucose homeostasis.  
 
Insulin signaling to Akt also activates Mechanistic target of rapamycin complex 1 
(mTORC1), a protein kinase that promotes cellular growth and proliferation via 
modulation of protein and lipid synthesis (11, 29). To enhance mTORC1 activation, Akt 
phosphorylates and inhibits two negative regulators of mTORC1, Proline-Rich Akt 
substrate of 40 kDa (Pras40) and Tuberous sclerosis complex 2 (Tsc2) (29). Akt-induced 
phosphorylation of Pras40 prevents Pras40 from binding to mTORC1 and thus relieves 
mTORC1 inhibition (30-33). Similarly, Tsc2 forms a complex with Tsc1 that acts as a 
GTPase-activating protein (GAP) to suppress Ras homolog enriched in brain (Rheb), a 
small G-protein that promotes mTORC1 signaling (34, 35). Activated Akt phosphorylates 
Tsc2 on several residues, preventing formation of the Tsc1/Tsc2 complex, therefore 
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increasing GTP-bound Rheb and allowing for mTORC1 activation (36-38). mTORC1 
promotes protein synthesis via direct phosphorylation of Ribosome protein S6 kinase 
(S6k) and Eukaryotic translation initiation factor 4E binding protein (4E-bp), resulting in 
activation of translation and ribosome biogenesis (39). mTORC1 phosphorylation of S6k 
promotes S6k kinase activity, leading to increased activation of downstream targets 
including Ribosomal protein S6, a component of the 40S ribosomal subunit, to promote 
translation (39, 40). 4E-bp is a cap-dependent translational repressor and mTORC1 
phosphorylation inhibits its activity (41). 4E-bp binds Eukaryotic translation initiation 
factor-4E (eIF4E), which is a rate-limiting initiation factor of translation, thus 4E-bp 
phosphorylation promotes dissociation from eIF4E and allows cap-dependent translation 
to initiate (41). A role for mTORC1 in lipid synthesis has also been clearly established; 
however, the mechanisms of action require further studies (42). Overall, insulin signaling 
to Akt relays the fed nutritional status of the animal to promote activation of anabolic 
processes via Akt and mTORC1 activation.  
 
Since the insulin signaling pathway promotes cellular growth, perturbations in this 
signaling pathway can lead to pathological conditions. Therefore, fine-tuning of the 
insulin-signaling pathway includes negative feedback mechanisms that are established to 
prevent chronic activation and uncontrolled growth (43, 44). Irs proteins can be 
phosphorylated at serine sites to prevent their association with the InsR and downstream 
effectors (45). Chronic serine phosphorylation of Irs proteins is therefore hypothesized to 
attenuate insulin signaling and promote insulin resistance (46). Protein kinase c (Pkc), 
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S6k1, and c-Jun NH2-terminal kinase (Jnk) are among the kinases proposed to promote 
Irs serine phosphorylation including at amino acid 307 to negatively regulate insulin 
signaling; however, evidence in vivo is lacking (47). Mice with a knock-in mutation of 
Irs-1 serine 307 to alanine, for example, cannot be serine phosphorylated at this site and 
therefore are predicted to display enhanced insulin sensitivity (48). However, when 
challenged with high-fat feeding, these animals are unexpectedly more insulin resistant 
than controls, demonstrating that negative-feedback mechanisms in the insulin-signaling 
pathway are complex in vivo (48). Other negative regulators of the insulin-signaling 
pathway have also been studied. Protein tyrosine phosphatases such as Protein tyrosine 
phosphatase 1B (Ptb1B) can also inhibit insulin signaling by dephosphorylating the InsR, 
effectively suppressing Irs recruitment function and insulin signaling (49). Suppressor of 
cytokine signaling proteins (Socs) can also inhibit insulin action via various mechanisms 
including competing with Irs proteins to bind InsR and targeting Irs proteins for 
proteosomal degradation, resulting in reduced in insulin signaling to Akt (50-52). 
Another major negative regulator of the insulin-signaling pathway is Phosphatase and 
tensin homolog (Pten), a lipid phosphatase that converts PIP3 to Phosphatidylinositol 4,5-
biphosphate (PIP2), thereby preventing Akt translocation to the plasma membrane and its 
full activation by Pdk1 and mTORC2 (53, 54). Pten is often mutated in cancers, 
enhancing Akt activation (53, 54). Thus, insulin signaling to Akt initiates anabolic 
pathways that need to be highly regulated to prevent uncontrolled growth.  
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Perturbations in this control of insulin signaling are a feature of insulin resistance, which 
frequently develops as a complication of obesity. Chronic over-nutrition and a sedentary 
lifestyle promote AT expansion, which can lead to low-grade inflammation and impaired 
ability of the adipose tissue to store lipids, leading to ectopic lipid deposition (55, 56). 
Obesity-induced inflammation occurs in various tissues including adipose tissue, skeletal 
muscle, liver, and hypothalamus (57). Pro-inflammatory cytokines can activate Jnk 
signaling, thus promoting Irs serine phosphorylation and suppression of insulin signaling 
to Akt (58-60). Lipid deposition in skeletal muscle and liver can result in increased levels 
of toxic lipid metabolites including ceramides and diacylglycerol (61, 62). These lipid 
metabolites can also activate signaling pathways such as Pkc and Jnk, which promote Irs 
serine phosphorylation and disruption of the insulin-signaling pathway, thus contributing 
to insulin resistance (11, 61). Ceramides can also inhibit insulin signaling to Akt by 
increasing Protein phosphatase 2A (Pp2a) activity, a phosphatase that dephosphorylates 
Akt, as well as by enhancing Pkc activity, which phosphorylates Akt and prevents its 
translocation to the plasma membrane, effectively reducing insulin signaling to Akt (63). 
Therefore ectopic lipid deposition results in heightened levels of toxic lipid metabolites 
that inhibit insulin signaling to Akt and promotes systemic insulin resistance.   
 
Inter-organ communication in the control of glucose homeostasis 
 
Although adipose tissue dysfunction plays a significant role in obesity-associated insulin 
resistance, it has also become clear that control of whole body homeostasis in animals 
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involves  complex interactions  among peripheral tissues both in the flow of nutrients as 
well as endocrine signals. Nutrient and hormonal signaling can also affect the central 
nervous system (CNS), which can impact feeding behaviors and energy metabolism (64, 
65); however, this will not be discussed in the present work. Instead I will focus on the 
metabolic and hormonal network involving the organs most relevant to this thesis: 
pancreas, adipose tissue, liver, and skeletal muscle. 
Pancreas  
The endocrine pancreas is responsible for the secretion of glucagon and insulin, two 
important hormones responsible for the maintenance of appropriate blood glucose levels. 
The Islets of Langerhans comprise approximately 1-2% of the entire pancreas; these 
clusters of cells are composed of β-cells (insulin-secreting) surrounded by α-cells 
(glucagon-secreting), δ- cell (somatostatin-secreting) and pancreatic peptide-cells (PP-
cells) (66). These islets are responsible for sending hormonal signals that orchestrate 
systemic glucose metabolism.  
 
In fasting conditions, α-cells secrete glucagon to stimulate catabolic pathways that restore 
glucose levels. α-cells are equipped with KATP channels that are active under low glucose 
levels, opening voltage-dependent T- and N-type Ca2+ channels, triggering action 
potentials, Ca2+ influx, and glucagon secretion via exocytosis (67). Due to the high 
vascularization of the pancreas, glucagon readily diffuses into the circulation, where it 
stimulates the liver to enhance glucose production (68). Genetic mouse models with 
deficiencies in glucagon secretion display hypoglycemia, as the liver lacks the activation 
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signals necessary to promote hepatic glucose production (5). Prohormone Convertase 2 
(PC2) post-translationally cleaves preproglucagon, resulting in the maturation of 
preproglucagon hormone (69, 70). PC2-null mice therefore display hypoglucagonemia 
and an inability to promote hepatic glucose production, resulting in hypoglycemia (71). 
Hypoglycemic conditions are restored following administration of exogenous glucagon, 
demonstrating that glucagon secretion is essential in maintaining euglycemic conditions 
(72).  
 
A glucose surge, on the other hand, inhibits glucagon release and promotes insulin 
secretion. Glucagon release is inhibited via various mechanisms including direct effects 
of glucose on the secretory function of α-cells (73-75), intra-islet paracrine factors 
including Zn2+ and insulin (67, 76, 77), and central nervous system signaling (78-80). 
Insulin is secreted in a biphasic manner to release the appropriate insulin concentrations 
needed to stabilize glucose levels (81). During the first phase of insulin secretion, glucose 
enters β-cells via rapid facilitated diffusion and is quickly metabolized, increasing the 
ATP:ADP ratio and causing KATP channels to close (82). The closure of KATP channels 
increases the intracellular concentration of positive ions, leading to depolarization of the 
β-cell and activation of voltage-gated Ca2+ channels (82). The activation of voltage-gated 
Ca2+ channels increases intracellular Ca2+ concentrations, triggering the export of insulin-
storing granules via exocytosis (82). During the second wave of insulin secretion, insulin 
must be synthesized, processed, and secreted, therefore this wave of secretion usually 
occurs approximately 30 minutes after initial glucose surge (83). Furthermore, recent 
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evidence suggests that this wave of insulin secretion may be independent of KATP 
channels (84); thus, future studies will address the molecular mechanisms employed by 
the second wave of insulin secretion. After secretion, insulin travels in the circulation to 
peripheral tissues including liver, skeletal muscle, and adipose tissue, signaling via InsR 
to promote anabolic processes including glucose uptake, lipid synthesis, and glycogenesis 
that remove and store glucose from the blood. 
 
Because of this vital role of insulin in reducing blood glucose, obesity-induced insulin 
resistance results in hyperglycemic conditions that in turn lead to a compensatory 
increase in insulin secretion (12, 13). During the β-cell compensatory response, enhanced 
β-cell expansion (via proliferation and neogenesis) and increased insulin biosynthesis 
promote elevated circulating insulin levels in an attempt to restore glucose homeostasis 
(12). Much research has been devoted to understanding the molecular mechanisms 
governing β-cell expansion, as patients that are unable to sustain this compensatory 
response develop T2D (12, 14). Continuous nutrient overload and chronic low-grade 
inflammation promote β-cell dysfunction via various mechanisms including oxidative 
stress (85, 86), endoplasmic reticulum (ER) stress (87, 88), toxic effects of high glucose 
and lipid levels (glucolipotoxicity) (75, 89), and amyloid accumulation (90, 91). Obesity 
is associated with chronic low-grade inflammation that enhances the circulatory levels of 
pro-inflammatory cytokines (92-94). Pancreatic inflammation can also be associated with 
obesity (93, 95), and local inflammatory stimuli such as Interleukin-1 beta (IL-1β) can 
signal to promote β-cell dysfunction and death (96, 97). Chronic over nutrition can also 
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be detrimental to β-cells, as excess glucose and lipids can promote mitochondrial 
overstimulation, leading to elevated levels of reactive oxygen species (ROS) (98). β-cells 
are highly sensitive to ROS levels due to low expression of antioxidant enzymes (99); 
thus, enhanced ROS concentrations can further stimulate inflammatory pathways and 
promote DNA damage, resulting in β-cell death. Therefore, obesity-associated chronic 
low-grade inflammation and lipotoxicity are detrimental to β-cell function and promote 
the onset of β-cell failure and T2D.  
Adipose tissue  
The adipose tissue is a key metabolic organ that plays a pivotal role in maintaining 
metabolic homeostasis mainly due to its capacity to take-up, store, and release lipids 
according to the physiological energy demands of the organism (55, 56, 100-102). 
Human lipodystrophic syndromes and mouse genetic models lacking adipose tissue have 
confirmed the metabolic importance of adipose tissue in both humans and rodents (103-
105).  Despite extreme leanness, these subjects often display systemic insulin resistance, 
dyslipidemia, and severe hepatic steatosis due to decreased adipose lipid-buffering 
capacity that usually prevents lipotoxic damage to other tissues (106). Therefore, proper 
adipose tissue function is essential in maintaining metabolic homeostasis.  
 
In times of excess energy, insulin activates metabolic pathways that enhance glycolysis 
(conversion of glucose to acetyl-CoA), synthesis of FA (lipogenesis), and formation of 
TG (esterification) (107, 108). Akt activation in the adipocyte promotes Glut4 
translocation to the plasma membrane to enhance glucose transport (Figure 1.2, A) (26). 
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Although the molecular mechanisms by which insulin promotes Glut4 translocation to 
the cell surface are still not fully understood, Akt can phosphorylate and inhibit TBC1 
domain family 4 (Tbc1d4, also known as As160) (Figure 1.2, A) (109, 110). 
Tbc1d4/As160 is a negative regulator of Glut4 trafficking; thus, inhibited Tbc1d4/As160 
allows Glut4 to translocate to the plasma membrane promoting glucose flux into 
adipocyte (Figure 1.2, A) (111). Glucose can be converted to acetyl-CoA via glycolysis, 
which can be synthesized into FA (de novo lipogenesis) or be converted to glycerol-3-
phosphate, the backbone of a TG molecule (108). Insulin also promotes FA uptake from 
Very low-density lipoprotein (Vldl) and chylomicrons by increasing Lipoprotein lipase 
(Lpl) expression  – a lipase that facilitates uptake of lipoprotein-derived FAs – on the 
surface of endothelial cells (112, 113). Lastly, insulin also promotes lipid synthesis via 
enhanced transcription and maturation of lipogenic transcription factor Sterol regulatory 
element-binding transcription factor 1 (Srebp-1) (Figure 1.2, A) (114, 115), and 
hyperglycemic conditions promote Carbohydrate-responsive element-binding protein 
(Chrebp) activation (116). These two transcription factors, in turn, control the expression 
of a plethora of lipogenic enzymes necessary for all steps of lipid synthesis (114, 117-
120). Thus, insulin promotes the uptake of glucose and FAs, which will be converted and 
safely stored as TG.  
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Figure 1.2 Adipose signaling to maintain whole-body glucose homeostasis.  
  
Figure 1.2 Adipose signaling to maintain whole-body glucose homeostasis. (A) 
Effects of insulin signaling to Akt in adipose cells. Activated Akt promotes glucose 
transport via inhibition of TBC1 domain family 4 (Tbc1d4, also known as As160). 
Inhibited Tbc1d4/As160 promotes Glucose Transport Type 4 (Glut4) vesicles 
translocation to the cell surface to allow glucose flux into the cell. (B) Fasting-induced 
lipolysis in adipose cells. Catecholamines signal via G protein-coupled receptor to 
activate adenylate cyclase and increase cAMP levels. Elevated cAMP levels promote 
Protein Kinase A (Pka) activation, which triggers Hormone-sensitive Lipase (Hsl) and 
Perilipin 1 (Plin1) activation, promoting the catalysis of triglycerides.    
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Various animal models have revealed the importance of adipose tissue insulin-stimulated 
glucose disposal and lipid synthesis. Transgenic animals that overexpress Glut4 in 
adipocytes display enhanced glucose uptake (even in the absence of insulin stimulation) 
and improved glucose homeostasis, highlighting the importance of adipose-mediated 
glucose  uptake in regulating circulating glucose levels (121, 122). Furthermore, animal 
models that enhance adipose lipid-buffering capabilities, either via adiponectin 
overexpression or forced expression of an adipose-specific dominant-active Pparγ 
transgene, also display improved metabolic parameters due to enhanced lipid 
sequestration, despite enhanced adiposity (123, 124). These animal models suggest that 
the ability of adipose tissue to sequester lipids protects peripheral organs from 
lipotoxicity and metabolic abnormalities.  
 
In fasting conditions, glucose uptake and lipid synthesis are suppressed while lipolysis is 
activated (125). Catecholamines signal in adipose cells to stimulate lipolysis, the 
breakdown of triglycerides to release FAs into the circulation for other metabolically 
active tissues to utilize as oxidative fuel (Figure 1.2, B) (126-130). Catecholamines bind 
to β-adrenergic receptors that are present in adipocytes, promoting adenylate cyclase 
activity and production of cAMP (Figure 1.2, B) (127-130). cAMP subsequently binds 
and sequesters the regulatory subunits of  Protein Kinase A (Pka), allowing the catalytic 
subunits to phosphorylate and activate downstream effectors such as Hormone-sensitive 
lipase (Hsl) and Perilipin 1 (Plin1) (Figure 1.2, B) (131, 132). Activation of Hsl and Plin1 
results in catalysis of TGs into FA and glycerol, which are subsequently released into the 
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circulation (Figure 1.2, B) (133). As an anabolic hormone, insulin inhibits this catalytic 
process (134). Insulin activates Akt, which activates phosphodiesterase 3B (Pde-3b), an 
enzyme that hydrolyzes cAMP, effectively lowering cAMP levels and reducing Pka 
activation (Figure 1.2, B) (135, 136). Akt also phosphorylates protein phosphatase 1 
(Pp1), a phosphatase that dephosphorylates and inactivates Hsl (Figure 1.2, B) (137-139). 
Deregulated adipose lipolysis can therefore lead to excess FAs in the circulation resulting 
in ectopic lipid deposition and insulin resistance (140). 
 
Besides its key lipid-buffering metabolic functions, the adipose is an endocrine organ that 
generates and secretes a plethora of bioactive factors (more than 600 molecules have 
been discovered) that can regulate a wide range of physiological processes including 
blood pressure, glucose and lipid metabolism, inflammation, atherosclerosis, appetite, 
and energy balance in various distant targets including liver, skeletal muscle, pancreas, 
and the cardiovascular system (141-143). The two most well studied adipokines (adipose-
secreted factors) are leptin and adiponectin. The circulating concentrations of leptin 
reflect adipose tissue energy stores, with increasing leptin concentrations indicating 
increased adipose mass (144, 145). Leptin signals to other tissues to regulate processes 
such as satiety, appetite, food intake, energy expenditure, and fertility (146). Thus, 
mutations in the leptin gene result in extreme obesity both in rodents and humans (147). 
For example, the ob/ob mouse model harbors a missense mutation in the leptin gene that 
disrupts leptin secretion and causes obesity due to incessant food intake and reduced 
energy expenditure (144, 145, 148). Adiponectin is another well-known adipokine that 
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promotes insulin sensitivity (149-151). Unlike leptin, adiponectin secretion negatively 
correlates with adipose size (i.e., more adipose tissue results in less adiponectin secretion) 
(152, 153). Adiponectin inhibits hepatic glucose production, promotes muscle glucose 
uptake, increases fatty-acid oxidation, promotes insulin secretion, and dampens 
inflammation (154). Thus, decreased adiponectin secretion, as occurs in Adiponectin-KO 
mice, results in exaggerated metabolic dysfunction with extreme hyperinsulinemia and 
glucose intolerance (155-157). Furthermore, adipose cells also generate lipokines (lipids 
secreted from adipose) via de novo lipogenesis, that enhance local and systemic glucose 
metabolism (158). Palmitoleate (C16:1n7) is a lipokine that is suggested to suppress 
hepatic steatosis and thus promote systemic insulin sensitivity (159). Therefore, the 
endocrine function of adipose tissue is critical maintaining whole-body glucose 
homeostasis.  
 
These vital functions of adipose tissue can be compromised in obesity. Obesity-induced 
insulin resistance is associated with a dysfunctional adipose tissue – deregulated lipolysis, 
reduced insulin-stimulated glucose transport, altered adipokine secretion, and suppressed 
lipid synthesis (55, 56, 160). Increased food intake and decreased energy expenditure 
promote adipose tissue expansion and immune cell infiltration (8-10). Various obesity-
related mechanisms have been proposed to contribute to the initiation of adipose tissue 
inflammation including lipotoxicity (161), ER stress (162, 163), adipocyte cell death 
(164), and hypoxia (165). The adipose tissue is composed of various cell types including 
adipocytes, fibroblasts, immune cells, and the vasculature. In a lean and healthy state, 
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macrophages in the adipose tissue are anti-inflammatory and promote insulin sensitivity 
by secreting Interleukin 10 (IL-10) (166). IL-10 attenuates pro-inflammatory cytokine 
signaling by inhibiting Nuclear factor kappa-light-chain-enhancer of activated B-cells 
(NF-κB), a key regulator of inflammatory gene expression (167). Obesity increases the 
number of adipose tissue macrophages and shifts the balance to a pro-inflammatory state 
(M1-macrophages), releasing pro-inflammatory cytokines such as Tumor necrosis factor-
alpha (Tnf-α) (168). Pro-inflammatory cytokines, in turn, promote adipose dysfunction 
by enhancing lipolysis and repressing lipid synthesis, creating a vicious feed-forward 
cycle whereby immune cells secrete inflammatory cytokines that promote adipose tissue 
dysfunction, and adipose tissue dysfunction promotes adipose tissue immune cell 
infiltration and proliferation. Pro-inflammatory cytokines can also activate signaling 
pathways such as Jnk, which promote Irs serine phosphorylation and dampen insulin 
signaling to Akt, resulting in detrimental effects on glucose homeostasis (47). Lastly, 
adipokine production is altered in obesity, releasing pro-inflammatory adipokines that 
attract immune cells into the adipose tissue and promote insulin resistance (141). 
Therefore, proper adipose tissue function (lipolysis, lipogenesis, and adipokine secretion) 
is essential in maintaining whole-body glucose homeostasis.  
Liver  
The liver is a critical organ that maintains blood glucose homeostasis via uptake, storage, 
and output of glucose (169). The liver also performs de novo lipogenesis to synthesize 
TG and package these into Vldl vesicles that will be transported to the adipose tissue for 
storage (170). While glucagon promotes the breakdown of glycogen to produce glucose, 
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insulin promotes glycogen formation and lipid synthesis; thus, proper liver function is 
essential in maintaining whole-body metabolic homeostasis.  
 
In fasting conditions, the liver produces glucose to maintain optimal systemic blood 
glucose levels (171). Two proteins are well recognized to be necessary for the 
transcriptional regulation of hepatic glucose production, cAMP response element-binding 
protein (Creb) and Forkhead box protein O1 (Foxo1) (5, 172). In fasting animals, α-cells 
secrete glucagon resulting in liver G-protein-coupled receptor (Gpcr) activation and 
increased adenylate cyclase activity, elevating cAMP levels (Figure 1.3, A) (5, 172). 
cAMP then activates Pka, which subsequently phosphorylates and activates Creb (173). 
Creb phosphorylation recruits transcriptional co-activators, Creb-binding protein (CBP), 
E1A binding protein p300 (p300), Creb-regulated transcription coactive 2 (Crtc2), and 
Pparγ-coactivator 1a (Pgc-1α), thus promoting the transcription of essential 
gluconeogenic genes including Phosphoenolpyruvate carboxykinase (Pepck) and 
Glucose-6-phosphatase (G6pc) (172). Furthermore, activated Akt negatively regulates 
Foxo1 transcription factors via direct phosphorylation, which causes cytoplasmic 
sequestration of Foxo1 proteins (174-176). Thus, in the absence of insulin in fasting 
conditions, Foxo1 transcription factors translocate to the nucleus to enhance 
gluconeogenic gene expression (174-176). Glucagon also signals in the liver to 1) inhibit 
glycolysis by decreasing the expression of Fructose 2,6-biphosphate (F-2,6-Bp), which 
decreases phosphofructokinase-1 (Pfk1) concentrations (177-179), 2) decrease glycogen 
formation by lowering glycogen synthase (Gs) expression (180, 181), and 3) promote 
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amino acid uptake (alanine, glycine, and proline), which can be converted to glucose via 
the gluconeogenic pathway (5). 
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Figure 1.3 Liver signaling to maintain glucose homeostasis.  
  
Figure 1.3 Liver signaling to maintain glucose homeostasis. (A) Glucagon signaling 
to promote hepatic glucose production. Glucagon signaling increases adenylate 
cyclase activity, resulting in elevated cAMP levels. Heightened cAMP levels promote 
Pka activation; resulting in cAMP response element-binding protein (Creb) 
phosphorylation and nuclear recruitment to promote gluconeogenic gene expression. In 
the absence of insulin, Forkhead box protein O1 (Foxo1) transcription factors are also 
able to translocate to the nucleus to promote gluconeogenic gene expression. (B) 
Insulin signaling to Akt in the liver. Activated hepatic Akt promotes glycogen and 
lipid synthesis and suppresses gluconeogenesis. To promote glycogen synthesis, Akt 
directly phosphorylates and inhibits Glycogen Synthase Kinase 3 (Gsk-3), thus 
relieving Gsk-3-induced inhibition of Glycogen Synthase (Gs). Activated Akt activates 
Phosphodiesterase 3b (Pde-3b), thus lowering cAMP levels, reducing Pka activation 
and Creb-induced gene expression. Akt also phosphorylates Forkhead Box Protein O1 
(Foxo1), which promotes Foxo1 cytosolic retention and reduces gluconeogenic gene 
expression. Activated Akt also promotes lipid synthesis via Mechanistic Target of 
Rapamycin (mTORC1) and Sterol regulatory element-binding transcription factor 1 
(Srebp-1) activation.  
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After feeding, a glucose surge promotes β-cell insulin secretion. Insulin binds to the 
hepatic InsR where it elicits a wide range of cellular responses including glycogen 
formation, suppression of glucose production, and lipid synthesis (Figure 1.3, B) (182). 
Insulin promotes glycogen formation by suppressing Pka activity and inhibiting 
Glycogen synthase kinase-3 (Gsk-3), resulting in increased Gs activity (183-185). Gs is a 
tetrameric enzyme that catalyzes the formation of glycogen from glucose (186). Pka and 
Gsk-3 can both phosphorylate and inhibit Gs, resulting in reduced glycogen formation 
(184, 187, 188). Insulin signaling to Akt activates Pde-3b, lowering cAMP levels and Pka 
activity, and promoting glycogen formation (136). Akt also phosphorylates and inhibits 
Gsk-3 activity, allowing for Gs activation and glycogen formation (189). To suppress 
gluconeogenesis, insulin promotes the lowering of cAMP levels, resulting in reduced 
Creb activation (173). Insulin also phosphorylates Foxo1 proteins, promoting their 
binding to cytosolic 14-3-3 proteins, resulting in Foxo1 nuclear exclusion (190). The end 
result of insulin signaling is therefore to suppress gluconeogenic gene expression. Insulin 
can also promote other processes including lipid synthesis via Akt activation, similar to 
the adipose tissue (191). Enhanced Akt signaling results in mTORC1 activation, which in 
turn promotes Srebp-1c cleavage and activation (42, 192). Srebp-1c is an important 
lipogenic transcription factor that resides in the ER, and proteolytic cleavage allows the 
NH2-terminus to translocate to the nucleus and bind to the sterol response elements 
(SRE) of various lipogenic genes including Acetyl-CoA carboxylase (Acc), Fatty acid 
synthase (Fasn), Stearoyl-CoA desaturase-1 (Scd-1), Pparγ, and Elongation of long chain 
fatty acids family member 6 (Elovl6) (42, 193). Newly produced TGs are then secreted 
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via Vldl particles for the adipose tissue to store (170). Due to the major effects on glucose 
production and lipid synthesis, proper hepatic insulin signaling is critical in maintaining 
whole-body glucose homeostasis. 
 
Obesity can promote peripheral insulin resistance and the liver is unique in that it 
becomes selectively insulin resistant (194). While insulin fails to suppress hepatic 
glucose production, allowing blood glucose levels to rise, hepatic lipid synthesis is 
protected, resulting in excessive lipid accumulation (18, 115). Hepatic steatosis can be 
ameliorated, however, via liver specific deletion of Scap proteins (195). Scap proteins 
transport Srebp-1 to the Golgi to be proteolytically cleaved depending on the stimuli, thus 
Scap is required for Srebp-1 processing (196). Liver-Scap KO mice have reduced nuclear 
Srebp-1 and decreased lipogenic gene expression, resulting in less hepatic steatosis and 
better metabolic homeostasis (195).  
Skeletal Muscle 
The skeletal muscle accounts for approximately 40% of body mass in a lean individual 
and functions to promote movement, maintain posture, stabilize joints, and generate heat 
(197). To properly function, the skeletal muscle requires energy; thus, in the post-
prandial state, it is the major site for glucose disposal, taking approximately 75% of 
ingested glucose via insulin-stimulated glucose uptake (198, 199). Therefore, insulin 
action on skeletal muscle can have profound effects on systemic glucose control.  
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During fasting conditions and energy-demanding processes such as exercise, epinephrine 
signals in the skeletal muscle to promote glycogen breakdown (Figure 1.4, A). 
Epinephrine signaling enhances adenylate cyclase activity and increases cAMP levels 
(200). cAMP promotes Pka activation, resulting in phosphorylation and increased activity 
of phosphorylase kinase (Phk) (200). Phk, in turn phosphorylates phosphorylase b, 
converting it into the active form phosphorylase a, which promotes the cleavage of 
glucose from glycogen (200). Glycogen breakdown, therefore, releases glucose, which is 
then rapidly oxidized by the muscle for energy. Furthermore, during glycogen 
breakdown, hexokinase (Hk) activity is inhibited by Glucose 6-phosphate (G-6-P), 
resulting in reduced glucose uptake and glucose phosphorylation (201). Muscle glycogen 
breakdown is therefore essential in providing energy as well as preventing removal of 
glucose from the circulation in fasting conditions. 
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Figure 1.4 Muscle signaling to maintain glucose homeostasis. 
  
Figure 1.4 Muscle signaling to maintain glucose homeostasis. (A) Epinephrine 
signaling to promote glycogenolysis. Epinephrine stimulates adenylate cyclase 
activity, effectively increasing cAMP levels and promoting Pka activation. Activated 
Pka phosphorylates Phosphorylase kinase (Phk), thus promoting cleavage of glucose 
from glycogen. (B) Insulin signaling to Akt promotes glucose transport and 
glycogen synthesis. Activated Akt promotes Glut4 translocation to the cell surface, 
thus promoting glucose influx. Activated Akt also promotes glycogen synthesis by 
phosphorylating and inhibiting Gsk-3 as well as by reducing Pka activity. Both Gsk-3 
and Pka inhibit Gs and glycogen synthesis.   
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In the post-prandial state, secreted insulin binds to the skeletal muscle InsR and signals 
via Akt to promote Glut4 translocation in a similar manner to the adipose tissue (Figure 
1.4, B) (26). Skeletal muscle glucose transport is mediated by Glucose transporter 1 
(Glut1), which is basally expressed at the plasma membrane, and Glut4, which 
translocates to the cell surface upon insulin stimulation (26). As expected, enhanced 
skeletal muscle glucose transport observed in either muscle-specific Glut4-transgenic 
(122, 202, 203) or muscle-specific Glut1-transgenic mice (204) significantly improves 
whole-body glucose homeostasis, reinforcing the importance of skeletal muscle glucose 
transport in whole-body metabolism. Glucose disposal in the skeletal muscle occurs via 
glucose oxidation (glycolysis and TCA cycle) and glycogen formation (205). Insulin 
signaling to Akt promotes glycogen formation in a similar manner as the liver, via 
phosphorylation and inhibition of Gsk-3 and reduced Pka activity (189). Both of these 
proteins phosphorylate and inhibit Gs, thus insulin signaling to Akt relives Gs 
suppression and allows for glycogen formation (206).  
 
The skeletal muscle also has endocrine functions as it secretes myokines, which are 
muscle-derived molecules that can exert autocrine, paracrine, and endocrine effects 
(207). Although our knowledge on myokines is still limited, they can have profound 
effects on insulin sensitivity. For example, Fibroblast growth factor 21 (Fgf-21) can be 
secreted from the skeletal muscle and improve metabolic functions by increasing 
circulating adiponectin levels (208). Interleukin-6 (IL-6) can also be secreted from the 
skeletal muscle, mostly after muscle contraction, and although the role of Il-6 in whole-
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body glucose homeostasis is controversial, IL-6 may have autocrine functions during 
exercise to promote muscle glucose uptake (207). Other myokines include irisin, which is 
secreted after exercise and induces white-to-brown adipose conversion to promote insulin 
sensitivity (209), Follistatin-like 1 (Fstl1), which has been shown to be cardioprotective 
(207), and brain-derived neurotrophic factor (Bdnf), which may have autocrine roles to 
enhance skeletal muscle fatty-acid oxidation (210). Many of the above mentioned 
myokines are critical in maintaining insulin sensitivity, however, inter-organ 
communication networks, including myokine secretion, is altered in obesity contributing 
to metabolic dysfunction (207).  
 
Elevated circulating FAs can promote muscle insulin resistance (211). Lipid infusion into 
lean human subjects results in decreased PI3K activation, reduced insulin-stimulated 
glucose uptake and insulin resistance (211). FAs can promote insulin resistance via 
various mechanisms including ectopic lipid accumulation (both ceramides and 
diacylglycerides), oxidative stress, chronic low-grade inflammation, and mitochondrial 
dysfunction (85, 211). All of these processes can result in suppression of the insulin-
signaling pathway, reducing insulin-stimulated glucose uptake and contributing to 
hyperglycemic conditions and metabolic dysfunction.  
Map4k4 
 
Insulin action on the skeletal muscle and the adipose tissue is essential in regulating 
systemic glucose levels (26, 122). Insulin signaling to Akt promotes Glut4 translocation 
to the cell surface, allowing glucose to enter the cell to restore euglycemia. Since T2D is 
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associated with defects in insulin action, including glucose-uptake, understanding the 
mechanisms by which insulin regulates Glut4 trafficking may have profound effects in 
the treatment of insulin resistance and T2D. Thus, previous colleagues in the Czech 
laboratory performed a siRNA screen aimed at identifying novel regulators (including 
kinases) of insulin-mediated glucose uptake (Figure 1.5, A) (212). In a lean and healthy 
mammal, the skeletal muscle is responsible for approximately 75% of insulin-mediated 
glucose disposal (13). However, mice with muscle-specific ablation of the InsR 
(MIRKO), despite reduced glucose uptake and insulin signaling, do not display major 
metabolic abnormalities (213). On the other hand, enhanced adipose glucose uptake 
observed in adipose-specific Glut4 transgenic mice, results in improved glucose tolerance 
and insulin sensitivity (121, 122). Previous colleagues in the Czech laboratory therefore 
performed the siRNA screen in cultured 3T3-L1 adipocytes (212). Using siRNA-
mediated gene silencing, the expression of 249 protein kinases expressed in cultured 
adipocytes was reduced and the effects on basal and insulin-stimulated deoxyglucose 
uptake assessed (Figure 1.5, A) (212). Interestingly, Mitogen-activated protein kinase 
kinase kinase kinase (Map4k4) silencing significantly increased insulin-stimulated 
glucose uptake, thus identifying Map4k4 as a novel negative regulator of glucose 
transport and insulin action in adipocytes (Figure 1.5, A) (212). 
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Figure 1.5 Protein Kinase Map4k4. 
  
Figure 1.5 (A) Map4k4 identified as repressor of glucose transport. siRNA-based 
screen to identify novel regulators of insulin action. Cells were transfected with 
respective siRNA. 72hrs post-transfection, cells were stimulated with insulin and 
glucose transport assayed with 3H-deoxyglycose. Adapted from Tang et al., 2006. (B) 
Map4k4 predicted domain structure. Map4k4 contains 1233 amino acids. The kinase 
domain of Map4k4 is in the NH2 terminus, while the Citron homology (CNH) domain 
is in the COOH terminus.   
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Map4k4 (also known as Hepatocyte progenitor kinase-like/germinal center kinase-like 
kinase (HGK) and Nck-interacting kinase (NIK)) is a serine/threonine protein kinase that 
was first identified as an interacting partner of the adaptor protein Nck (214). Map4k4 is 
located on chromosome 1 (1B) in mice (chromosome 2 in humans) and encodes a protein 
containing 1288 amino acids with 33 exons, although alternative splicing resulting in 
different isoforms has been reported (215). Structurally, Map4k4 contains a SH3 domain, 
citron-homology domain (CNH), and two putative caspase cleavage sites, however the 
function of these structures has not been thoroughly studied (Figure 1.5, B) (216).  
 
Ste20-related protein kinases   
Based on homology and signature sequence in subdomain VIII (GTP(Y/F/C)WMAPE), 
Map4k4 and 27 other mammalian serine/threonine protein kinases belong to the Ste20-
related protein kinase family (217). In Saccharomyces cerevisiae, Ste20p is a protein 
involved in a wide variety of processes including pheromone response and migration 
(216). All related mammalian kinases also have diverse and wide-ranging functions 
including ion transport, cell cycle, cytoskeletal organization, and programmed cell death 
(217, 218).  
 
Based on the location of the catalytic domain, Ste20-related kinases are further 
subdivided into two groups—in p21-activated kinases (PAKs), the catalytic domain is in 
the -COOH-terminus, whereas in germinal center-like kinases (GCKs), the catalytic 
domain in the NH2-terminus (217). Because the catalytic domain of Map4k4 is in the 
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NH2-terminus, Map4k4 is a member of the GCK family and belongs to subgroup IV 
based on the most shared sequence with Traf2 and Nck-interacting protein (Tnik) and 
Mishapen-like kinase 1 (Mink), 92% and 87%, respectively (219).  
 
Biological functions  
In keeping with the yeast Ste20p cellular functions, Map4k4 is implicated in various 
physiological cellular processes including migration, inflammation, and cellular 
metabolism (220). Although the molecular targets and signaling pathways for Map4k4 
are still under investigation, a conserved role for Map4k4 in cellular migration has been 
established. In Caenorhabditis elegans, Map4k4 (MIG-15) regulates neuroblast migration 
(221, 222), while in Drosophila melanogaster Map4k4  (Misshapen) regulates dorsal 
closure, neuronal targeting, and cell invasion (223-225). In mammals, whole-body 
Map4k4-null mice display early embryonic lethality due to the failure of mesodermal 
cells to migrate away from the primitive streak (214). Consistent with a role for Map4k4 
in promoting cellular motility increased Map4k4 expression in cancerous tissue correlates 
with worse prognosis due to increased likelihood of metastasis (226-228). The molecular 
targets of Map4k4 to promote cellular motility are still under investigation, however a 
role for Map4k4 in regulating both F-actin polymerization dynamics via Actin-related 
protein (Arp) 2/3 complex phosphorylation and microtubule and focal adhesion dynamics 
via ADP-ribosylation factor 6 (Arf6) activation has been reported (229, 230).  
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Map4k4 is also reported to inhibit insulin action and cellular metabolism. Our laboratory 
identified Map4k4 as a negative regulator of glucose uptake and insulin action in cultured 
adipocytes (212). Consistent with a role for Map4k4 as a repressor of insulin action, 
Map4k4 has been suggested to be a cellular mediator of inflammatory cytokines such as 
Tnf-α (231-233). For example, Map4k4 depletion in macrophages in vivo attenuates 
systemic inflammation and prolongs survival after a Lipopolysaccharides (LPS) 
challenge (231). In C2C12 muscle cells, Map4k4 inhibits muscle differentiation (234), 
and in mature human myotubes, Map4k4 depletion protects from Tnf-α-induced insulin 
resistance (232). Finally, in cultured β-cells, Map4k4 silencing protects cells from 
reduced insulin secretion caused by Tnf-α (233). Thus, these studies suggest Map4k4 
may suppress insulin action and Map4k4 inhibition in vivo may ameliorate obesity-
induced metabolic dysfunction. A recent publication, however, suggests Map4k4 may 
function to suppress, rather than promote, inflammation (235). Using a T-cell specific cre 
line to generate T-cell specific Map4k4 knockout mice, knockout mice develop systemic 
inflammation due to stabilization of Tnf receptor-associated factor 2 (Traf2) and IL-6 
overproduction (235). Future studies will be required to assess the cell-type specific 
functions of Map4k4 and their role in metabolic disease.
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Project Goals 
 
Controlled glucose homeostasis is an elaborate physiological process that requires inter-
organ communication. Our laboratory is particularly interested in understanding novel 
regulators of adipocyte function as these signaling nodes can significantly contribute to 
systemic glucose control and alternations in these pathways promote metabolic disease. 
To identify such signaling nodes, previous colleagues in the Czech laboratory used a 
siRNA-based screen in cultured adipocytes and identified the protein kinase Map4k4 as a 
negative regulator of insulin action. Furthermore, they found that the metabolic 
consequences of Map4k4 depletion in adipocytes included increased glucose transport. 
Therefore the experiments performed in this thesis are aimed at dissecting the role of 
Map4k4 in the adipocyte, identifying key signaling pathways downstream of 
Map4k4, and defining how the actions of Map4k4 in these signaling pathways may 
regulate whole-body metabolism. We are specifically interested in Map4k4 as it is a 
potential novel therapeutic target for the treatment of metabolic disease, where there is a 
need for new therapies.   
 
Two main questions are addressed in this thesis: 
1. Does Map4k4 affect adipocyte-specific functions? If so, what are the specific 
signaling mechanisms involved? 
2. What is the role of Map4k4 in regulation of whole-body glucose and lipid 
metabolism? Do the actions of Map4k4 contribute to the metabolic dysfunction 
associated with obesity and insulin resistance?  
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To answer these questions, the studies reported in this thesis utilize both in vitro and in 
vivo models to investigate the role of Map4k4.  In cultured adipocytes, I found that 
Map4k4 represses lipid synthesis independent of glucose transport, and these effects are 
mediated via mTORC1- and Srebp-1-dependent mechanisms (Chapter II) (236). Contrary 
to initial expectations, I found that Map4k4 does not repress lipid synthesis via the Jnk 
signaling cascade. I also showed that Map4k4 is not an upstream regulator of Jnk, and 
further demonstrated that prior work placing Map4k4 as an upstream positive regulator of 
Jnk was based on artifactual overexpression (Chapter II) (236). Based on the effects 
observed in vitro, where Map4k4 suppresses glucose transport and lipid synthesis, I 
assessed the role of Map4k4 in vivo and tested whether Map4k4 deletion would protect 
obese mice from metabolic disease. In fact, I found that Map4k4 deletion improved 
glucose tolerance in high-fat diet fed mice. Consistent with the in vitro studies in cultured 
adipocytes in Chapter II, where Map4k4 signals to inhibit insulin action, I also found that 
systemic Map4k4 depletion in adult mice improves whole-body insulin sensitivity 
(Chapter III). I generated multiple tissue-specific Map4k4 KO mice and observed that 
Map4k4 ablation in Myf5-positive cells, which include skeletal muscles, recapitulates the 
improved systemic insulin sensitivity observed in systemic Map4k4-ablated mice, while 
ablation of Map4k4 in adipocytes or hepatocytes had no such effect (Chapter III). 
Therefore, Map4k4 regulates signaling nodes in Myf5-positive cells that alter whole-
body metabolism. Thus, Map4k4 may serve as a novel drug target in the treatment for 
T2D.  
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CHAPTER II: 
Map4k4 suppresses lipogenic transcription factor Srebp-1 and 
adipose lipid synthesis independent of the Jnk signaling 
cascade. 
 
 
 
 
 
 
 
 
 
 
This chapter is derived from the article of the same name that appeared in publication in 
the Journal of Lipid Research:  
Laura V. Danai, Adilson Guilherme, Kalyani V. Guntur, Juerg Straubhaar, Sarah M. 
Nicoloro, and Michael P. Czech, J Lipid Res. 2013. 54(10):2697-2707. 
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Summary 
 
Adipose tissue lipogenesis is paradoxically impaired in human obesity, promoting ectopic 
triglyceride (TG) deposition, lipotoxicity, and insulin resistance. We previously identified 
Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4), a Sterile 20 protein 
kinase reported to be upstream of c-Jun NH2-terminal kinase (Jnk) signaling, as a novel 
negative regulator of insulin-stimulated glucose transport in adipocytes. Using full-
genome microarray analysis we uncovered a novel role for Map4k4 as a suppressor of 
lipid synthesis. We further report that Map4k4 suppresses adipocyte lipogenesis 
independently of Jnk. While Map4k4 silencing in adipocytes enhances the expression of 
lipogenic enzymes, concomitant with increased conversion of 14C-glucose and 14C-
acetate into TG and fatty acids (FA), Jnk1 and Jnk2 depletion causes the opposite effects. 
Furthermore, high expression of Map4k4 fails to activate endogenous Jnk, while Map4k4 
depletion does not attenuate Jnk activation by Tnf-α. Map4k4 silencing in cultured 
adipocytes elevates both the total protein expression and cleavage of Srebp-1 in a 
rapamycin-sensitive manner, consistent with Map4k4 signaling via Mechanistic target of 
rapamycin complex 1 (mTORC1). We show Map4k4 depletion requires Srebp-1 
upregulation to increase lipogenesis and further show that Map4k4 promotes Ampk 
(AMP-protein kinase) signaling and the phosphorylation of mTORC1 binding partner 
Raptor (Ser 792) to inhibit mTORC1. Our results indicate that Map4k4 inhibits adipose 
lipogenesis by suppression of Srebp-1 in an Ampk- and mTOR-dependent but Jnk-
independent mechanism.  
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Introduction 
 
Obesity can promote adipose dysfunction, which paradoxically results in decreased 
adipose lipid synthesis and contributes to ectopic lipid deposition and whole body insulin 
resistance (105). Lipodystrophic human subjects and mouse models demonstrate that 
deficits in adipose lipid synthesis (lipogenesis) correlate with excess lipid deposition and 
whole-body insulin resistance, highlighting the importance of adipose lipogenesis in 
metabolic dysfunction (103, 105, 237, 238). The expression and activity of the lipogenic 
transcription factors peroxisome proliferator-activated receptor gamma (Pparγ), sterol-
regulated element binding protein-1 (Srebp-1), and carbohydrate responsive element-
binding protein (Chrebp, also known as Mlxipl) are suppressed in the adipose tissue of 
obese humans, resulting in decreased expression of lipogenic enzymes and decreased 
adipose fatty acid (FA) and triglyceride (TG) synthesis; however, the mechanisms that 
lead to this inhibition are still unclear (237-244). Therefore, understanding this 
deregulation is fundamental in developing strategies that enhance adipose lipogenesis and 
lipid sequestration, thus preventing the ectopic lipid deposition and insulin resistance that 
occurs during obesity.    
 
Srebp-1 and Srebp-2 are transcription factors important for regulating the expression of 
genes involved in the synthesis and uptake of cholesterol, FA, TG, and phospholipids 
(117). These factors reside in the endoplasmic reticulum (ER) and upon demand for lipid 
synthesis are transported to the Golgi apparatus to be post-translationally cleaved, 
allowing the functional NH2-terminal fragment to translocate into the nucleus and 
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regulate lipogenic gene expression (117). Srebp transcription factors have distinctive 
specificities: Srebp-2 mainly controls expression of genes involved in the cholesterol 
biosynthetic pathway, while Srebp-1 mainly controls lipogenic gene expression; 
however, overlap in function has been reported (117, 196). Srebp-1 is an important 
regulator of lipogenesis as it controls the expression of lipogenic genes including solute 
carrier family 2 (facilitated glucose transporter) member 4 (Slc2a4 or Glut4) (245), ATP 
citrate lyase (Acly) (246), acetyl-Coenzyme A carboxylase alpha (Acaca) (247), fatty 
acid synthase (Fasn) (248, 249), stearoyl-Coenzyme A desaturase 1 (Scd-1) (250), 
glycerol-3-phosphate acyltransferase (Gpat) (251), and Pparγ (252, 253). As a regulator 
of anabolic processes, Srebp-1 is positively regulated by mechanistic target of rapamycin 
(mTORC1) (254-257) and negatively regulated by AMP-protein kinase (Ampk) (258-
260). Although the mechanism by which mTORC1 promotes Srebp-1 activity is not fully 
understood, increased Pparγ function in response to mTORC1 activation may contribute 
to increased Srebp-mediated adipose lipogenesis (254, 261-266).  
 
In an attempt to find novel modulators of insulin action, our laboratory performed an 
siRNA screen to identify regulators of insulin-stimulated glucose transport in adipose 
cells. Depletion of Mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) 
significantly enhanced glucose transport, thus Map4k4 was discovered as novel negative 
regulator of glucose transport. Map4k4 is a serine/threonine protein kinase related to 
Saccharomyces cerevisiae Sterile 20 (Ste 20) protein kinases. Previous work suggests 
Map4k4 is a pro-inflammatory kinase that activates c-Jun NH2-terminal kinase (Jnk) 
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protein kinase (267-269). This would be in keeping with a role for Map4k4 as a Ste20-
like protein kinase, upstream of the MAP kinase-signaling pathway (216, 217, 270). 
Map4k4 has also been reported to inhibit mTORC1, resulting in decreased Pparγ protein 
levels (261). Interestingly, Map4k4 expression increases in the adipose tissue of obese 
subjects, while adipose lipogenesis decreases (271). We therefore aimed to test the role of 
Map4k4 in adipose lipogenesis and whether its actions require mTORC1 or the Jnk 
signaling pathway. These studies extend our previous understanding of Map4k4 function 
and demonstrate that Map4k4 suppresses lipogenesis in an mTORC1-dependent and Jnk-
independent manner.  
Materials and methods 
 
Materials and Chemicals – Bovine insulin, FA-free BSA, D-glucose, sodium pyruvate, 
and sodium acetate were purchased from Sigma. Tnf-α was purchased from Calbiochem. 
14C-U-glucose (250 µCi/mL) and 14C-acetate (250 µCi/mL) were purchased from Perkin 
Elmer. Flag-Jnk1 and Flag-Jnk2 were developed by R. Davis (University of 
Massachusetts Medical School) (Addgene plasmid 13798 and 13801, respectively) (272, 
273). 
Cell Culture – 3T3-L1 fibroblasts were grown and differentiated into adipocytes as 
previously described (274). Briefly, 3T3-L1 fibroblasts were grown to confluence in 
complete media (high glucose (25mM) DMEM containing 10% fetal bovine serum, 50 
units/mL penicillin and 50 µg/mL of streptomycin).  Two days after confluence, 
differentiation media (0.25 µM dexamethasone, 0.5 mM 1-methyl-3-isobutylxanthine, 
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and 10-7 M insulin) was added. On the fourth day after differentiation media was added, 
adipocytes were either infected with 40 µL of 1.43 X 1012 particles/mL of adenovirus 
(AdCMV-HA-Control or AdCMV-HA-Map4k4, University of Massachusetts Medical 
School Viral Vector Core Facility, the CMV driven adenoviral vector expresses Map4k4 
with an NH2-terminal triple HA epitope tag) or washed with PBS, trypsinized, and 
transfected by electroporation (Bio-Rad Gene Pulser II – 0.18 kV, 960 microfarads) with 
siRNA (Scrambled, Map4k4, Jnk1/2, Srebp1/2 from Dharmacon). A green fluorescent 
protein (GFP)-expressing control virus or Map4k4 D152N-expressing virus were also 
used and added at a dose of 40 µL of 1.43 X 1012 particles/mL for 72hr. These 
adenoviruses were gifts from Diane L. Barber (Department of Cell and Tissue Biology, 
University of California, San Francisco, CA. Transfection of HEK 293T cells was 
achieved using Lipofectamine 2000 (Invitrogen) following the manufacturer’s protocol. 
Briefly, cells were plated at a density of 2.5 X 105 cells per 6-well plate a day before 
transfection. 1 µg of DNA was used for each transfection and empty vector was used to 
achieve equal amounts of DNA between conditions. Knockdown experiments in HEK 
293T cells were achieved using Lipofectamine RNAi Max (Invitrogen), following the 
manufacturer’s protocol.  
RNA Isolation, Real Time PCR, Affymetrix Gene Chip Analysis– Total RNA was 
extracted from adipocytes using TriPure isolation reagent (Roche) following 
manufacturer’s instructions. cDNA was synthesized using iScript cDNA Synthesis Kit 
(BioRad) and quantitative RT-PCR was performed using iQ SybrGreen supermix and 
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analyzed as previously described (275, 276).  36B4 (Rplp0) and Hprt served as 
housekeeping internal controls.  
For Affymetrix Gene Chip analysis, RNA was isolated from three independent 
experiments and hybridized to three different murine genome MOE430-2 microarrays. 
RNA quality was measured using the Agilent 2100 Bioanalyzer. Differentially expressed 
mRNAs were identified using a random-variance t-test. 
siRNA Duplexes – siRNA sequences were purchased from Dharmacon RNAi 
Technologies (Thermo Scientific). Scramble control 
(CAGUCGCGUUUGCGACUGGUU), Map4k4 (GACCAACUCUGGCUUGUUAUU), 
Jnk1 (GGAGUUAGAUCAUGAAAGAUU), Jnk2 
(GGAAAGAGCUAAUUUACAAUU), Srebp1 (Srebf1) SMARTpool 
(GGGCAGCUCUGUACUCCUU; 
GUACACUUCUGGAGACAUC; CAAACAAGCUGACCUGGAU; 
GCAAGGCCAUCGACUACAU), Srebp2 (Srebf2) SMARTpool 
(GAGGAAGGCCAUUGAUUAC; GGUGCAACCUCAGAUCAUU; 
GAAAGUUCCUAUCAAGCAA; CCAGUGCUCUAGAGUAUUU) 
Immunoblotting –For studies on Jnk signaling, cells were treated with 50 ng/mL Tnf-α 
for 15 minutes. Cells were washed twice in cold PBS and collected in RIPA buffer 
supplemented with protease and phosphatase inhibitors (Thermo Scientific). Total cell 
lysates were resolved by SDS-PAGE and electro-transferred to nitrocellulose membranes. 
Membranes were incubated with indicated antibodies overnight at 4°C. Blots were 
washed with TBST (0.1% Tween 20 in Tris-Buffered saline), incubated with horseradish 
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peroxidase anti-mouse or anti-rabbit secondary antibody and visualized using enhanced 
chemiluminescent substrate kit (Perkin Elmer). Densitometry analyses were performed 
using ImageJ. For experiments on insulin signaling, 3T3-L1 adipocytes were washed 
twice with PBS and 2 mL of low glucose DMEM (2.5% FA free BSA, 1% (v/v) 
Pen/Strep, 0.5mM D-Glucose, 0.5mM Sodium Acetate, 2mM sodium pyruvate) was 
added in all wells. 1 µM insulin was added to corresponding wells for 1.5 hr. Phospho-
Jnk and Jnk, DYKDDDDDK Tag, HA, phospho-4E-bp and total 4E-bp, phospho-S6 and 
total S6 antibodies were purchased from Cell Signaling. Phospho-cJun and cJun 
antibodies were purchased from Santa Cruz. Actin and Flag M2 antibodies were 
purchased from Sigma and Map4k4 antibody was purchased from Bethyl (#A301-503A).  
Srebp Immunoblotting- Srebp-1 antibody was purchased from Millipore (Clone 2121) 
and Srebp-2 was purchased from Cayman Chemical (#10007663). A minimum of 30µg 
of protein lysates (2% SDS, 150 mM NaCl and 5mM EDTA) was resolved by SDS-
PAGE (8%) and electrotransferred to nitrocellulose membranes. Membranes were 
incubated with indicated antibodies overnight at 4°C (1:1000). Blots were washed with 
TBST (0.1% Tween 20 in Tris-Buffered saline), incubated with horseradish peroxidase 
anti-mouse (for Srebp-1) or anti-rabbit secondary antibody (for Srebp-2) (1hr) and 
visualized using enhanced chemiluminescent substrate kit (Perkin Elmer). It is important 
to note that a non-specific band is recognized by Srebp-2 that could be mistaken as the 
cleaved Srebp-2 protein. Srebp-1 antibody occasionally recognizes a non-specific band 
circa 75 KDa.  
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In Vitro Protein Kinase Assay –Map4k4 kinase assays were performed by lysing cells 
(20mM Tris (pH 7.5), 150mM NaCl, 1 mM EDTA, 1 % Triton X-100, 2.5 mM sodium 
pyrophosphate, 1mM β-glycerophosphate, 1mM Sodium Orthovanadate and 1 µg/mL 
leupeptin) and precipitating Map4k4 with HA antibody (Cell Signaling) and protein A 
agarose beads. Precipitates were washed 4 times and mixed with 40 µL kinase buffer 
(20mM Hepes pH 7.4, 10mM MgCl2, 20mM β-glycerophosphate, 10mM NaF, 0.2mM 
Sodium Orthovanadate, 1mM DTT), 5 µg unphosphorylated MBP (Millipore), 250 µM 
ATP, and 1µCi/reaction ATP. Kinase reactions were performed at 30°C for 30 minutes 
and terminated with addition of SDS sample buffer and heating the samples to 95°C for 5 
minutes. Reaction mixtures were resolved by SDS-PAGE and transferred to a 
nitrocellulose membrane for autoradiogram and western blot analysis.  
Radiolabeled Glucose and Acetate Conversion to TG and FA – The incorporation of 
the various radioactive substrates into TG and FA was measured as previously described 
(277). In brief, adipocytes were washed twice with PBS and 1 mL of labeling media 
(2.5% FA free BSA, 1% (v/v) Pen/Strep, 0.5mM D-Glucose, 0.5mM Sodium Acetate, 
2mM sodium pyruvate, 2 µCi/mL 14C-U-glucose or 14C-acetate) was added. Final 
concentration of 1µM insulin was added to insulin-stimulated conditions. Cells were 
incubated at 37°C in a humidified incubator (5% CO2) for 4.5 h before lipid extraction.  
All metabolic processes were stopped by washing cells twice with cold PBS and lysing 
cells by the addition of modified Dole’s extraction mixture (80 mL isopropanol, 20 mL 
hexane, 2 mL of 1N H2SO4) (278).  Triglycerides were extracted with hexane, washed, 
and the solvent was evaporated. Incorporation of 14C-glucose or 14C-acetate into FA of 
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TG was determined by evaporating the solvent from the neutral lipids, adding 1 mL 
KOH-ethanol (20 mL of 95% ethanol, 1 mL water, 1 mL saturated KOH), and heating 
samples to 80°C for 1 hr. Sulfuric acid was added to the mixture to ensure complete 
saponification. Addition of hexane allowed hydrophobic separation, which was 
evaporated and counted by liquid scintillation. Incorporation data were normalized to cell 
number.   
Thin Layer Chromatography – TG and FA were separated by TLC using hexane: ethyl 
ether: acetic acid (200:50:4). Autoradiography was performed with TG and FA standards. 
The silica gel from each radiolabeled spot was subsequently scraped and quantified by 
liquid scintillation.  
Results 
 
Map4k4 depletion enhances metabolic gene expression  
We have previously shown that Map4k4 depletion enhances Pparγ protein expression and 
TG accumulation in cultured adipocytes (212, 261). To further investigate the effects of 
Map4k4 depletion, we used Affymetrix Mouse MOE430-2 microarrays to compare gene 
expression between scrambled-siRNA versus Map4k4-siRNA treated mature 3T3-L1 
adipocytes. KEGG Gene Set Enrichment Profiles using scrambled siRNA versus Map4k4 
siRNA-treated adipocytes indicated that the most upregulated genes upon Map4k4 
depletion are enriched in metabolic pathways (Pathway 01100), valine, leucine and 
isoleucine degradation (Pathway 00280), peroxisome biosynthesis (04146), glycolysis 
(Pathway 00010), pyruvate metabolism (Pathway 00620), fatty acid metabolism 
(Pathway 00071), insulin signaling pathway (Pathway 04910), and the TCA cycle 
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(Pathway 00020)(Figure 2.1, A). We further validated the mRNA expression of several 
lipogenic genes upon Map4k4 depletion in cultured adipocytes (Figure 2.1, B). These 
analyses suggest that Map4k4 suppresses lipid metabolism-related processes in cultured 
adipocytes.  
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Figure 2.1 Map4k4 depletion enhances metabolic gene expression. 
  
Figure 2.1 Map4k4 depletion enhances metabolic gene expression. (A) KEGG 
gene set enrichment profile of differentially expressed genes upon Map4k4 
depletion (P<.05, fold change 1.3) in murine 3T3-L1 mature adipocytes. The table 
shows the pathways that were most significantly upregulated by Map4k4 depletion. 
The gene list contains genes involved in each pathway and the genes in green 
further represent genes that were significantly upregulated within the specific 
pathway upon Map4k4 depletion. (B) RT-qPCR analysis of metabolic genes upon 
Map4k4 depletion in mature cultured adipocytes. 
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Map4k4 functions as a repressor of triglyceride synthesis in cultured adipocytes  
To further assess the role of Map4k4 as a negative regulator of TG synthesis in 
adipocytes, we depleted Map4k4 in mature 3T3-L1 adipocytes using siRNA or elicited 
increased Map4k4 expression using adenovirus vectors, and measured the conversion of 
14C-glucose into neutral lipids.  Consistent with the hypothesis that Map4k4 inhibits lipid 
synthesis, Map4k4 depletion resulted in approximately 50% increased incorporation of 
the 14C-radiolabel into neutral lipids compared to scrambled control (Figure 2.2, A). 
Conversely, Map4k4 overexpression significantly reduced 14C-radiolabel incorporation 
into TG by ~29% compared to the adenovirus HA-control (Ad: HA-control) (Figure 2.2, 
A). To determine whether Map4k4 was suppressing glycerol-3-phosphate (G-3-P) 
formation or de novo lipogenesis, we measured 14C-radiolabel incorporation into both FA 
of TG (Figure 2.2, B) and glyceride-glycerol (Figure 2.2, C). We determined that 
Map4k4 inhibited both glyceride-glycerol formation and de novo lipid synthesis in 
mature adipocytes as seen by increased incorporation of the radiolabel into both 
molecules upon Map4k4 depletion and decreased incorporation upon Map4k4 
overexpression (Figure 2.2, B-C). We also confirmed that these observed changes in 
neutral lipid synthesis and de novo lipogenesis reflect changes in TG and FA, 
respectively, by TLC analysis (data not shown).  
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Figure 2.2 Map4k4 represses triglyceride synthesis in cultured adipocytes. 
 
Figure 2.2 Map4k4 represses triglyceride synthesis in cultured adipocytes. (A-C) 
14C-glucose conversion into TG (A), FA (B), and glyceride-glycerol (C) is shown. Cells 
were transfected by electroporation with scrambled (7.5 µM) or Map4k4 (7.5 µM) siRNA 
(N=9) or were infected with control virus (Ad: HA-Ctl) or HA-Map4k4 adenovirus (Ad: 
HA-Map4k4) (N=4). 72 hrs. post-transfection, cells were incubated with 14C-glucose for 
4hr and triglycerides extracted. (D-E) 14C-acetate conversion into TG (D) and FA (E) is 
shown; lipids were extracted as (A). (F) Representative immunoblots depicting Map4k4 
protein expression upon siRNA transfection or adenoviral overexpression. Samples were 
noncontiguous on the same gel.  The data are represented as the average +/- SE and were 
compared to appropriate controls by Student’s T-test.  ****P<. 0001, **P<. 01.   
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We have previously reported that Map4k4 silencing increases Glut4 expression and 
glucose uptake (212), possibly providing the substrate for both glyceride-glycerol and 
fatty acid synthesis. To distinguish whether Map4k4 regulates lipid synthesis independent 
of glucose flux, we used either control or Map4k4 siRNA-transfected adipocytes and 
measured 14C-acetate incorporation into TG. 14C-acetate incorporation into TG is a 
measure of de novo lipogenesis as the radiolabel bypasses glucose transport and 
metabolism and provides the substrate for FA synthesis. Consistent with Map4k4 
inhibiting lipid synthesis, Map4k4 depletion significantly increased 14C-acetate 
incorporation into TG and its constituent FA (Figure 2.2, D-E). Representative protein 
immunoblots confirmed Map4k4 knockdown or overexpression at the protein level 
(Figure 2.2, F). These results indicate that Map4k4 is a negative regulator of glucose flux, 
de novo FA synthesis, and TG synthesis in cultured adipocytes.  
 
Map4k4 silencing does not enhance lipid synthesis via Jnk signaling  
Map4k4 has been proposed to be a pro-inflammatory kinase and upstream positive 
regulator of the Jnk signaling cascade (267-269). Because the role of adipose Jnk in lipid 
synthesis has not been clearly established, we tested whether Map4k4 repressed 
lipogenesis via Jnk. We hypothesized that if Map4k4 was an upstream activator of Jnk, 
then Jnk depletion would enhance lipid synthesis compared to scrambled control, similar 
to Map4k4 depletion. 3T3-L1 adipocytes were electroporated with scrambled siRNA or 
siRNA against Map4k4 or Jnk1 and Jnk2, and 14C-acetate incorporation into FA and TG 
was used to assess the role of these kinases in TG synthesis and de novo lipogenesis. 
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Consistent with results shown in Figure 2.2, Map4k4 depletion significantly increased 
14C-acetate incorporation into TG (Figure 2.3, A-B). Surprisingly, depletion of the two 
major isoforms of Jnk, Jnk1 and Jnk2, significantly reduced TG synthesis by 56%, 
opposite to the effects observed upon Map4k4 silencing (Figure 2.3, A-B). Furthermore, 
14C-acetate incorporation into FA, a measure of de novo lipogenesis, was significantly 
increased upon Map4k4 silencing (~47%) and decreased upon Jnk depletion (~20%) 
(Figure 2.3, A, C). Efficient Map4k4 and Jnk protein depletion was confirmed by protein 
immunoblots (Figure 2.3, D). Therefore, these data demonstrate that while Map4k4 
downregulates lipogenesis, Jnk1 and Jnk2 are required for this process. We next 
examined whether Jnk and Map4k4 depletion affected lipogenic gene expression in a 
dissimilar fashion using RT-qPCR (Figure 2.3, E). Consistent with the effects observed 
using 14C-acetate, Map4k4 depletion significantly enhanced the mRNA expression of 
Srebp-1, Chrebp, Fasn, Scd-1, Pepck, and Glut4, while Jnk depletion decreased the 
mRNA expression of these genes (Figure 2.3, E). These results indicate that Map4k4 is a 
repressor of adipose lipogenesis while Jnk is an unexpected positive regulator of this 
metabolic process. Furthermore, Map4k4 does not repress lipogenesis in a Jnk-dependent 
manner.  
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Figure 2.3 Map4k4 does not regulate lipid synthesis via Jnk. 
 
Figure 2.3 Map4k4 does not regulate lipid synthesis via Jnk. (A) Autoradiogram of 
TLC analysis of TG and FA extracted from adipocytes that were transfected with 
scrambled siRNA, Jnk1 and Jnk2 siRNA, or Map4k4 siRNA. 72 hrs. post transfection, 
adipocytes were incubated with 14C-acetate and incorporation into TG and FA was 
determined. Samples were noncontiguous on the same TLC plate. (B-C) Changes in 14C-
acetate incorporation into TG (B) and FA (C) in Jnk- and Map4k4-depleted mature 
adipocytes relative to Scrambled control. (D) Representative immunoblots for Map4k4 
and Jnk protein expression in control, Map4k4- and Jnk-depleted cells. (E) RT-qPCR 
analysis of lipogenic gene expression in control, Map4k4- and Jnk-depleted adipocytes 
relative to scrambled control siRNA-treated cells (N=5). Data are presented as average 
+/- SE and were compared between groups by Student’s T-test. * P<. 01, ** P<. 001, *** 
P<. 0001.  
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Map4k4 does not activate the Jnk signaling pathway in adipocytes  
These divergent effects of Map4k4 and Jnk were unexpected in light of previous reports 
that suggest Map4k4 functions as an upstream activator of Jnk in various cell models 
(267-269). To further investigate whether increased Map4k4 expression and activity 
would be sufficient to increase endogenous Jnk signaling in adipocytes, we used 
adenoviral-mediated Map4k4 overexpression followed by stimulation with tumor 
necrosis factor alpha (Tnf-α), a potent Jnk activator (Figure 2.4). Despite increased 
expression and activity of Map4k4 (Figure 2.4, A), phosphorylation of Jnk and its 
downstream substrate cJun did not differ between empty virus (Ad: HA-control) and 
Map4k4 adenoviral (Ad: HA-Map4k4)-treated adipocytes in both basal and Tnf-α-treated 
conditions (Figure 2.4, B). Thus, while increased Map4k4 expression and activity 
inhibited TG synthesis (Figure 2.2), it was not sufficient to alter endogenous Jnk 
signaling in adipocytes. Furthermore, if Map4k4 is a required upstream activator of Jnk, 
Map4k4 depletion should attenuate Jnk activation in response to Tnf-α treatment. 
Map4k4 depletion, however, did not attenuate Jnk activation (Figure 2.4, C) or affect the 
expression of activator protein-1 (AP-1) transcriptional factors – cJun, C-fos, and JunD – 
in response to Tnf-α (Figure 2.4, D). As expected and consistent with previous results 
(279), Jnk depletion attenuated the maximal response of these AP-1 transcriptional 
factors in response to Tnf-α (Figure 2.4, D). These results indicate that Map4k4 is neither 
sufficient nor required to induce Jnk activation in adipocytes. Furthermore, using gain-of-
function approaches in HEK 293T cells, we show that co-transfection of both Map4k4 
and Jnk increases Jnk activity, consistent with published results (Figure 2.5, A-B); 
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however, depletion of endogenous Map4k4 does not diminish Jnk activity (Figure 2.5, 
C), suggesting that Map4k4 is not an endogenous modulator of Jnk signaling. These 
results support the notion that endogenous Map4k4 is not required for optimal 
endogenous Jnk activation in adipocytes or HEK 293T cells, but that artificially high 
levels of exogenously expressed Map4k4 and Jnk can enhance Jnk signaling.  
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Figure 2.4 Map4k4 is neither necessary nor sufficient for canonical Jnk signaling.   
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Figure 2.4 Map4k4 is neither necessary nor sufficient for canonical Jnk 
signaling.  (A) Map4k4 kinase activity in control and Map4k4-overexpressing 
adipocytes stimulated with Tnf-α for 30 min. (B) Protein immunoblots of 
control and Map4k4-overexpressing adipocytes treated with 50 ng/mL Tnf-α 
for 15 min (N=4). Samples were noncontiguous on the same gel. (C) Protein 
immunoblot of electroporated adipocytes treated with control, Map4k4 or Jnk1 
and Jnk2 siRNA and stimulated with 50 ng/mL Tnf-α for 15 min (N=4). (D) 
RT-qPCR analysis of AP-1 transcription factors in response to 50 ng/mL Tnf-α 
treatment in control, Map4k4-depleted or Jnk-depleted adipocytes (N=3).   
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Figure 2.5 Ectopic Jnk and Map4k4 expression enhances Jnk signaling. 
  
Figure 2.5 Ectopic Jnk and Map4k4 expression enhances Jnk signaling. (A) 
Protein immunoblots depicting Jnk activation in response to 50ng/mL Tnf-α in 
HEK 293T cells transfected with equal amounts of empty vector, HA-Map4k4, 
Flag- Jnk1 or Flag- Jnk2 constructs (N=3). (B) Quantification of (A). (C) 
Map4k4 was depleted in HEK 293T cells using siRNA and cells were stimulated 
with 1 ng/mL and 50 ng/mL Tnf-α for 15 min. Protein immunoblots depicting Jnk 
activation are shown (N=3). 
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Map4k4 inhibits lipid synthesis in an mTORC1-dependent manner  
We have previously demonstrated that Map4k4 impairs mTORC1 signaling (261) and 
since mTORC1 signaling enhances lipid synthesis (254, 256, 266, 280), we tested 
whether Map4k4 required mTORC1 to inhibit lipid synthesis. We depleted Map4k4 using 
siRNA and treated cells with rapamycin, an mTOR inhibitor, to repress mTORC1 
signaling. Consistent with previous reports, Map4k4 depletion enhanced mTORC1 
signaling as demonstrated by increased ribosomal protein S6 (S6) and eukaryotic 
translation initiation factor 4E binding protein 1 (4E-bp1/Eif4ebp1) protein 
phosphorylation (261) (Figure 2.6, A). Interestingly, Map4k4 depletion also increased 
Srebp-1 protein levels, an important lipogenic transcription factor (Figure 2.6, A). 
Rapamycin treatment inhibited mTORC1 signaling, as evidenced by a lack of S6 and 4E-
bp1 protein phosphorylation, and abolished the increase in Srebp-1 protein expression 
that resulted from Map4k4 silencing (Figure 2.6, A). Rapamycin treatment also 
diminished the Map4k4 silencing-induced increase in 14C-glucose incorporation into TG 
(Figure 2.6, B) and FA (Figure 2.6, C). These results indicate that proper mTORC1 
function is necessary for Srebp-1 expression and optimal lipid synthesis in cultured 
adipocytes and support the notion that Map4k4 represses the mTORC1/Srebp pathway to 
inhibit adipose lipogenesis.  
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Figure 2.6. Map4k4 regulates mTORC1 to inhibit Srebp-1 expression and 
triglyceride synthesis. 
 
  
Figure 2.6 Map4k4 regulates mTORC1 to inhibit Srebp-1 expression and 
triglyceride synthesis. (A) 3T3-L1 adipocytes were electroporated with control 
siRNA or Map4k4 siRNA and treated with 100 nM rapamycin for 48 hrs. and/or 
insulin for 1.5 hrs. Protein immunoblots depicting insulin-induced Akt and 
mTORC1 activation and rapamycin-induced inhibition in control and Map4k4-
depleted adipocytes. (B-C) Incorporation of 14C-glucose into TG (B) and 
saponifiable FA (C) in control siRNA treated or Map4k4-depleted adipocytes 
treated with rapamycin. The data are represented as the average +/- SE and were 
compared between groups by Student’s T-test (N=4, *** P<. 0001). 
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Map4k4 depletion requires Srebp expression to enhance lipid synthesis  
We demonstrated that Map4k4 depletion enhances mTORC1 signaling and increases 
Srebp-1 protein expression (Figure 2.6, A). As an alternative approach to assess the effect 
of impaired Map4k4 function, we used a kinase-inactive mutant of Map4k4 (AdMap4k4 
D152N) (281), previously shown to function as a dominant-negative inhibitor (234). 
Consistent with silencing experiments using siRNA (Figure 2.6, A), Map4k4 D152N 
overexpression resulted in increased cleaved Srebp-1 protein levels (Figure 2.7, A-B). 
Similarly, adenovirus-mediated overexpression of wild-type Map4k4 results in decreased 
Srebp-1 protein levels (Figure 2.8, A) and decreased lipogenic gene expression (Figure 
2.8, B), consistent with reduced lipid synthesis (Figure 2.2, A-C). To determine whether 
Map4k4 depletion requires the increase in Srebp-1 protein to enhance lipid synthesis, we 
performed gene silencing experiments using siRNA to suppress either Map4k4, Srebp-1 
and Srebp-2, or Map4k4/Srebp-1/Srebp-2 expression in mature cultured adipocytes and 
examined conversion of 14C-glucose into TG and FA. Depletion of both Srebp-1 and 
Srebp-2 was required in these experiments because depletion of either transcription factor 
alone resulted in a compensatory increase by the other transcription factor (data not 
shown). Protein immunoblots demonstrated that Map4k4 knockdown resulted in a 
significant increase in precursor and cleaved Srebp-1 protein levels as well as an increase 
in total Srebp-2 protein levels (Figure 2.9, A). Consistent with Figure 2.1 (B) and Figure 
2.3. (E), Map4k4 silencing significantly increased the mRNA expression of known 
Srebp-1 lipogenic target genes including Acaca (~73%), Scd-1 (~78%), and Fasn (~23%) 
(247, 249, 250) (Figure 2.9, B). Interestingly, Map4k4 depletion requires Srebp 
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expression to increase lipogenic gene expression as depletion of Srebp-1 and Srebp-2 in 
the context of Map4k4 depletion severely blunted the enhanced expression of these 
lipogenic genes (Figure 2.9, B). Map4k4 depletion also significantly increased 14C-
glucose conversion into both TG (Figure 2.9, C) and FA (Figure 2.9, D), as demonstrated 
in previous figures, and depletion of both Srebp transcription factors significantly blunted 
the increase in radiolabel incorporation into TG and FA in response to Map4k4 silencing 
(Figure 2.9, C-D). Consistent with Srebp transcription factors regulating lipid synthesis, 
depletion of both Srebp-1 and Srebp-2 significantly reduced adipose lipogenesis as 
assessed by reduced radiolabel incorporation into TG and FA (Figure 2.9, C-D). These 
results indicate that Srebp proteins are necessary for optimal adipose lipogenesis and are 
also required to mediate the effects of Map4k4 on lipid synthesis. 
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Figure 2.7 Map4k4 kinase inactivity results in increased Srebp-1 protein levels. 
  
Figure 2.7 Map4k4 kinase inactivity results in increased Srebp-1 protein levels. (A) 
Representative Srebp-1 protein immunoblot of mature adipocytes infected with control or 
Map4k4 dead-kinase virus. 72 hrs. post-infection, cells were serum-starved for 2 hrs. and 
treated with 1 μM insulin for 3.5 hrs. (B) Quantification of A (N=3). Data are presented 
as average +/- SEM and compared between groups by Student’s T-test (*P<.05). 
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Figure 2.8 Increased Map4k4 expression and activity decreases lipid synthesis. 
 
Figure 2.8 Increased Map4k4 expression and activity decreases lipid synthesis. 
(A) Representative Srebp-1 protein immunoblot of control and Map4k4-
overexpressing adipocytes treated with 1 uM insulin for 3.5 hrs. (N=4). (B) RT-qPCR 
analysis of lipogenic gene expression in control and Map4k4-overexpressing 
adipocytes (N=4). Data are presented as average +/- SE and were compared between 
groups by Student’s T-test. * P<.01, ** P<.001.  
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Figure 2.9 Map4k4 regulates lipogenesis via Srebp. 
 
Figure 2.9 Map4k4 regulates lipogenesis via Srebp. (A) Mature 3T3-L1 adipocytes 
were transfected with control siRNA, Map4k4 siRNA, Srebp-1 and Srebp-2 siRNA, or 
Map4k4/Srebp-1/Srebp-2 siRNA and treated with 1 μM insulin for 1.5 hrs. Cells were 
harvested and Map4k4, Srebp-1, and Srebp-2 protein expression was analyzed by protein 
immunoblots. (B) RT-qPCR analysis of lipogenic gene expression in control, Map4k4, 
Srebp1 and Srebp2, and Srebp1, Srebp2 and Map4k4-depleted adipocytes. (C-D) 
Incorporation of 14C-glucose into TG (C) and FA (D) in control, Map4k4-depleted, 
Srebp-1 and Srebp-2 depleted or Map4k4/Srebp-1/Srebp-2 depleted adipocytes was 
measured. The data are represented as the average +/- SE and were compared between 
groups by Student’s T-test. (N=4, * P<. 01, ** P<. 001, *** P<. 0001). 
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Map4k4 is a positive regulator of Ampk.  
Map4k4 has been implicated as a positive regulator of Ampk activity (282), and Ampk is 
a negative regulator of mTORC1, suggesting a plausible mechanism by which Map4k4 
may negatively regulate mTORC1 and inhibit lipogenesis. We verified that Map4k4 
regulates Ampk signaling in cultured adipocytes by treating Map4k4-depleted adipocytes 
with oligomycin, an inhibitor of ATP synthase and potent activator of Ampk. As 
expected, treatment of adipocytes with oligomycin (500 nM for 30 minutes) increased 
Ampk phosphorylation. This response was significantly blunted in Map4k4-depleted 
adipocytes (Figure 2.10, A-B). Furthermore, decreased Ampk activation results in 
increased mTOR signaling (as assessed by decreased Raptor phosphorylation (Ser792)) 
and increased lipogenesis (as assessed by ACC phosphorylation (Ser79)) (Figure 2.10, 
A). Attenuation of Ampk signaling in response to Map4k4 depletion also occurs with 
other Ampk activators including glucose withdrawal and phenformin (data not shown). 
On the other hand, increased Map4k4 expression and activity results in increased Ampk 
signaling as assessed by increased pAmpk and pACC in response to oligomycin 
treatment (Figure 2.10, C). These results suggest Map4k4 is necessary for optimal Ampk 
activation and provide insights into the mechanism by which Map4k4 inhibits mTORC1 
and lipid synthesis in mature adipocytes.  
  
  33  
Figure 2.10 Map4k4 regulates Ampk signaling. 
 
Figure 2.10 Map4k4 regulates Ampk signaling. (A) Protein immunoblot of 3T3-L1 
adipocytes transfected with control siRNA or Map4k4 siRNA and treated with 500 nM 
oligomycin for 30 minutes (N=5). (B) Quantification of (A). (C) Protein immunoblot of 
3T3-L1 adipocytes infected with control virus (empty adenovirus) or HA-Map4k4 
adenovirus and treated with 500 nM oligomycin for 30 minutes (N=4). (D) Schematic 
model coupling Map4k4 to Ampk and mTOR to inhibit lipid synthesis. 
 
  34 
Discussion 
 
Here we show that adipose Map4k4 represses glucose incorporation into FA and TG, at 
least in part via Ampk regulation, which results in downregulation of mTORC1 function 
and Srebp-1 expression. We found that Map4k4 depletion enhances the conversion of 
both 14C-glucose and 14C-acetate into TG and FA (Figure 2.2, Figure 2.3), suggesting 
Map4k4 inhibits both de novo FA synthesis and FA esterification. Conversely, increased 
Map4k4 expression decreases the conversion of 14C-glucose into TG (Figure 2.2, A-C). 
We provide strong evidence to suggest that the ability of Map4k4 to repress adipose 
lipogenesis is independent of the Jnk signaling pathway, which we unexpectedly found to 
be required for optimal TG synthesis in cultured adipocytes (Figure 2.3). These findings 
have direct relevance to the adipose dysfunction, including chronic inflammation and 
impaired lipid storage capacity, that occurs with obesity, because Map4k4 expression is 
elevated with increasing body mass index (BMI) (271). This increased Map4k4 
expression could contribute to impaired lipid buffering (TG synthesis and storage) in 
obese adipose tissue. Upon evaluating underlying mechanisms of Map4k4 action, we 
show that Map4k4 is required for activation of Ampk signaling, which in turn is expected 
to modulate mTORC1 and Srebp-1 activity, and adipose lipogenesis. Thus, our results 
provide evidence for a model in which Map4k4 modulates Ampk, suppressing mTORC1 
function and Srebp-1 expression to depress lipogenesis (Figure 2.10, D).  
 
Our results are consistent with previous studies that describe a positive role of Jnk in 
adipose lipogenesis (283-285). Jnk1 depletion using anti-sense oligonucleotides in 
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adipose tissue attenuates the expression of lipogenic enzymes Acly, Acaca, Fasn, and 
Scd-1 (283) and Jnk2 suppression in human adipocytes attenuates Srebp-1 expression and 
activity resulting in decreased target lipid enzymes (285). Mice expressing a mature, 
transcriptionally active Srebp-1 variant lacking all of the Jnk phosphorylation sites are 
protected from hepatic steatosis and weight gain, thus demonstrating that Jnk positively 
regulates Srebp-1 function (286). Furthermore, Jnk is required for optimal Srebp-1 
activation and the subsequent increase in Scd-1 and Fasn in response to keratinocyte 
growth factor treatment (284). We have therefore confirmed the positive role of Jnk in 
adipose lipogenesis and have further established that Map4k4 does not require Jnk to 
inhibit TG synthesis. We also provide evidence that Map4k4 is neither required nor 
sufficient to activate endogenous Jnk signaling. Consistent with previous reports, we find 
that co-transfection of Jnk and Map4k4 enhanced Jnk signaling (267-269); however, 
increased Map4k4 activity and expression alone were not sufficient to activate 
endogenous Jnk, and Map4k4 depletion did not attenuate Tnf-α-induced Jnk activation 
(Figure 2.4). Therefore, our results suggest that Map4k4 is not an upstream activator of 
Jnk in cultured adipose cells or HEK 293T cells (Figure 2.5), and that previous results 
placing Map4k4 in the Jnk signaling pathway may be due to artificially high ectopic 
expression of both of these protein kinases.  
 
These results extend our previous findings that Map4k4 represses mTORC1 signaling in 
adipocytes (261) and shed insight into the mechanism by which Map4k4 represses lipid 
synthesis. The role of Srebp-1 in adipose lipogenesis has been largely dismissed because 
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Srebp-1 null animals form functional fat depots (287, 288). However, the loss of Srebp-1 
increases Srebp-2 expression and activity, compensating for the loss of Srebp-1 (287, 
288). Furthermore, while overexpression of the nuclear fragment of Srebp-1c causes 
lipodystrophy (289), overexpression of a different isoform, Srebp-1a, increases the 
expression of downstream lipogenic target genes such as Fasn and Scd-1 (290). Because 
we observed compensation of Srebp isoforms in cultured adipocytes (data not shown), we 
targeted both Srebp-1 and Srebp-2 to deplete lipogenesis (Figure 2.9). Interestingly, liver 
specific depletion of SCAP, a regulatory protein that is required for Srebp protein 
proteolytic cleavage, decreased Srebp-1 and Srebp-2 expression with a concomitant 
reduction in obesity-induced hepatic steatosis, consistent with the notion that depletion of 
both Srebp proteins is required to diminish lipogenesis (195, 291). Our results support an 
active role for Srebp-1 and Srebp-2 in adipose lipogenesis and demonstrate that Map4k4 
inhibits lipid synthesis via suppression of Srebp proteins (Figure 2.9).  
 
Mechanistically, it is unclear how mTORC1 regulates Srebp-1 function (254-257). 
Rapamycin, a general mTOR inhibitor, disrupts Srebp-1 expression and maturation, thus 
decreasing lipogenesis (254, 256, 263-265). We have previously shown that Map4k4 
inhibits mTORC1 function and we further show that this inhibition decreases Srebp-1 
expression (Figure 2.8) and adipose lipogenesis. Map4k4 depletion enhances protein 
translation in an mTORC1-dependent manner (261) and this may explain the increased 
Srebp-1 protein expression (both precursor and cleaved product) upon Map4k4 depletion. 
Interestingly, Map4k4 depletion does not affect Srebp-1 protein stability (data not shown) 
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as previously reported for Pparγ (261) and Myf5 (234). Furthermore, we provide data that 
suggests Map4k4 inhibits mTORC1 function via Ampk modulation. Map4k4 depletion 
attenuates Ampk signaling (Figure 2.10, A-B), resulting in decreased ACC and Raptor 
phosphorylation, translating into increased lipid synthesis. Thus, Map4k4 represses lipid 
synthesis in an mTORC1- and Srebp-1-dependent manner and this is independent of Jnk-
signaling. Because adipose tissue Map4k4 expression is increased during obesity (271), 
Map4k4 may be an important negative regulator of adipose lipogenesis in metabolic 
disease.  
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CHAPTER III: 
Inducible deletion of protein kinase Map4k4 in obese mice 
improves insulin sensitivity in liver and adipose tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is derived from the article of the same name that appeared in publication in 
Molecular and Cellular Biology:  
Laura V. Danai, Rachel J. Roth Flach, Joseph V. Virbasius, Lorena Garcia Menendez, , 
Dae Young Jung, Jong Hun Kim, Jason K. Kim, Michael P. Czech.Mol Cell Biol. 2015.  
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Summary 
 
Studies in vitro suggest that the protein kinase Map4k4 attenuates insulin signaling, but 
confirmation in vivo is lacking since global Map4k4 deletion is lethal during 
embryogenesis. We thus generated mice with floxed Map4k4 alleles and a tamoxifen-
inducible Cre/ERT2 recombinase under the control of the Ubiquitin C promoter to induce 
whole-body Map4k4 deletion after animals reach maturity. Tamoxifen administration 
induced Map4k4 deletion in all tissues examined, causing decreased fasting blood 
glucose concentrations and enhanced insulin signaling to Akt in adipose tissue and liver, 
but not skeletal muscle. Surprisingly, however, mice generated with conditional Map4k4 
deletion in adiponectin-positive adipocytes or in albumin-positive hepatocytes displayed 
no detectable metabolic phenotypes. Instead, mice with Map4k4 deleted in Myf5-positive 
tissues, including all skeletal muscles tested, were protected from obesity-induced 
glucose intolerance and insulin resistance. Remarkably, these mice also showed increased 
insulin sensitivity in adipose tissue but not skeletal muscle, similar to the metabolic 
phenotypes observed in inducible whole-body knockout mice. Taken together, these 
results indicate that, 1.) Map4k4 controls a pathway in Myf5-positive cells that 
suppresses whole-body insulin sensitivity and 2.) Map4k4 is a potential therapeutic target 
for improving glucose tolerance and insulin sensitivity in type-2 diabetes.   
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Introduction 
 
Whole-body glucose homeostasis in humans is maintained by an elaborate physiological 
system that involves multi-organ regulation. In the post-prandial state, glucose and amino 
acids induce β-cells in the pancreas to secrete insulin, promoting glucose uptake in 
skeletal muscle and adipose tissue while suppressing glucose production from the liver. 
These effects of insulin to maintain glucose homeostasis can be disrupted in obesity, 
causing an insulin-resistant state that contributes to elevated blood glucose levels and an 
increased incidence of type-2 diabetes (T2D) (292). While metformin (thought to mainly 
affect liver glucose metabolism) and insulin secretagogues are clinical mainstays for the 
treatment of T2D, further intervention is often required (15). Treatments that address the 
underlying peripheral insulin resistance in T2D are now limited due to contra-indications 
to the use of thiazolidinediones (TZDs), a major drug class that alleviates insulin 
resistance by targeting Peroxisome Proliferator-Activated Receptor (Pparγ) (16, 17). 
Thus, novel proteins that could be targeted with drugs to enhance peripheral insulin 
sensitivity would prove useful in developing therapies for T2D.  
 
In screening the adipocyte kinome for such negative regulators of insulin signaling to 
glucose transport in vitro, we identified Map4k4, a serine/threonine protein kinase with 
homology to yeast Ste20 protein kinases (212). Interestingly, single nucleotide 
polymorphisms (SNPs) in the Map4k4 locus appear to be associated with insulin 
resistance (293) and T2D (294). We therefore hypothesized that Map4k4 may be a novel 
therapeutic target for improving obesity-induced peripheral insulin resistance. The 
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functions of Map4k4 in insulin signaling and energy metabolism were subsequently 
studied in various cell culture models. In adipocytes, Map4k4 repressed glucose transport 
and lipid synthesis (212, 236) while in human myotubes, Map4k4 depletion protected 
cells from Tnf-α-induced insulin resistance (232). These studies suggested that systemic 
Map4k4 depletion might improve whole-body glucose metabolism in obesity. However, 
the effects of systemic Map4k4 deficiency on metabolic disease in vivo have not yet been 
studied due to the embryonic lethality of Map4k4-null mice (214). To circumvent this 
problem, we generated an inducible gene deletion mouse model to investigate the 
physiological effects of Map4k4 depletion once mice reach maturity. We sought to 
address several questions employing this model. First, is Map4k4 required for viability of 
adult mice? Second, is Map4k4 a negative regulator of systemic insulin sensitivity and 
metabolic function in obese animals? Lastly, in what tissue or tissues may Map4k4 
operate to modulate whole-body glucose homeostasis and insulin responsiveness?  
 
Here we report that mature mice with induced systemic Map4k4 ablation (iMap4k4-KO 
mice) are viable, and when challenged with high-fat feeding display lower fasting 
glucose levels and improved peripheral insulin sensitivity. By generating multiple tissue-
specific Map4k4 knockout mice, we found that Map4k4 deficiency in cells with a Myf5-
lineage, which include skeletal muscles, but not selective Map4k4 deficiency in adipose 
cells or hepatocytes, recapitulates the improved systemic insulin sensitivity observed in 
whole-body iMap4k4-KO mice.   
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Materials and methods 
 
Animal Studies 
All of the studies performed were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Massachusetts Medical School. Animals were 
maintained in 12hr light/dark cycle and fed standard chow (Lab diet 5P76) unless 
otherwise stated. Mice with conditional Map4k4 floxed alleles were generated as 
described elsewhere (295) and were backcrossed to C57BL/6J for at least 7 generations. 
To inactivate Map4k4 in adult mice, homozygous Map4k4flox/flox animals were crossed to 
B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J (Jackson Laboratories). 8wk-old mice (both 
Map4k4flox/flox and Map4k4-flox/flox-UBC-cre ERT2) were treated via intraperitoneal 
injection (IP) with 30μ g tamoxifen/40g body weight dissolved in corn oil for 5 
consecutive days. 2wks after first tamoxifen injection, animals were fed normal chow 
(ND) or high-fat diet (HFD) (12492i Harlan) for 16wks.  
Adiponectin-cre mice (B6;FVB-Tg(Adipoq-cre)1Evdr/J), Albumin-cre mice (C57BL/6-
Tg(Alb-cre)21Mgn/J) and Myf-5 cre mice (B6.129S4-Myf5tm3(cre)Sor/J) were obtained 
from Jackson Laboratories.  
Mice were fasted for 16hrs for GTT and PTT or 4hrs for ITT. Fasted mice were IP 
injected with glucose (1g/kg), pyruvate (1g/kg), or insulin (1 IU/kg). Blood samples were 
withdrawn by tail vein and blood glucose levels were determined using the Breeze-2-
glucose meter (Bayer).  
Metabolic cage and body composition analyses were performed by the UMass Mouse 
Metabolic Phenotyping Center. The metabolic cages were used to measure food and 
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water intake over a 3-day period and average food intake/day calculated (TSE Systems). 
Whole-body fat and lean mass was measured using 1H-MRS (Echo Medical System).  
RNA Isolation and RT-qPCR 
Total RNA was isolated from tissues using TriPure isolation reagent (Roche) following 
the manufacturer’s protocol. Isolated RNA was DNAse treated (DNA-free, Life 
Technologies), and cDNA was synthesized using iScript cDNA synthesis kit (BioRad). 
RT-qPCR was performed using iQ SybrGreen supermix and 36B4 (Rplp0) served as 
reference gene. Primer sequences are as follows: 
Rplp0 (5’–TCCAGGCTTTGGGCATCA–3’, 3’–
CTTTATCAGCTGCACATCACTCAGA–5’); Map4k4 (5’–
CATCTCCAGGGAAATCCTCAGG–3’, 3’–TTCTGTAGTCGTAAGTGGCGTCTG–
5’); Emr-1 (5’–CCCCAGTGTCCTTACAGAGTG–3’, 3’–
GTGCCCAGAGTGGATGTCT–5’); CD68 (5’–CCATCCTTCACGATGACACCT–3’, 
3’– GGCAGGGTTATGAGTGACAGTT–5’); Itgam (5’–
ATGGACGCTGATGGCAATACC–3’, 3’–TCCCCATTCACGTCTCCCA–5’); Itgax 
(5’–CTGGATAGCCTTTCTTCTGCTG–3’, 3’–GCACACTGTGTCCGAACTCA–5’); 
Il-1β (5’–GCAACTGTTCCTGAACTCAACT–3’, 3’–
ATCTTTTGGGGTCCGTCAACT–5’); CCL2 (5’–
TTAAAAACCTGGATCGGAACCAA–3’, 3’–GCATTAGCTTCAGATTTACGGGT–
5’); Tnf-α (5’–CAGGCGGTGCCTATGTCTC–3’, 3’–
CGATCACCCCGAAGTTCAGTAG–5’); Pepck (5’–
CTGCATAACGGTCTGGACTTC–3’, 3’–CAGCAACTGCCCGTACTCC–5’); G6pc 
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(5’–CGACTCGCTATCTCCAAGTGA–‘3, 3’–GTTGAACCAGTCTCCGACCA–5’); 
Gck (5’–TGAGCCGGATGCAGAAGGA–3’, 3’–GCAACATCTTTACACTGGCCT–
5’); Fasn (5’–GGAGGTGGTGATAGCCGGTAT–3’, 3’–
TGGGTAATCCATAGAGCCCAG–5’); Scd-1 (5’–
TTCTTGCGATACACTCTGGTGC–3’, 3’– CGGGATTGAATGTTCTTGTCGT–5’). 
Plasma analysis  
Mice were fasted overnight and plasma collected via cardiac puncture. Serum NEFA 
levels were measured using a colorimetric assay (Wako Diagnostics) according to 
manufacturer’s instructions. Alternatively, animals were injected with .5mg/kg CL 
316,243 (Santa Cruz) dissolved in PBS and blood was collected via the tail vein after 1hr. 
Insulin measurements were performed using an Insulin ELISA kit (Millipore) according 
to the manufacturer’s instructions.  
Histology  
Tissues were isolated and fixed in 10% formalin, paraffin embedded, sectioned, and 
stained with hematoxylin and eosin (H&E). The UMass Morphology Core performed the 
embedding and sectioning.  
Adipocyte isolation 
Adipose tissue was minced in digestion buffer (5% BSA, 1mg/mL collagenase (Sigma, 
#C6885) in HBSS) and digested in a 37°C water-bath for 30-45 minutes. Digested 
tissue was filtered through a 200μm nylon mesh and centrifuged at a low speed for 5 
minutes. Floating adipocytes were washed several times in HBSS followed by 
centrifugation.  
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Hepatocyte isolation 
Hepatocytes were isolated as previously described (296). Briefly, chow-fed animals were 
anesthetized via IP ketamine/xylazine injection. Livers were perfused then digested with 
50mg/mL collagenase (Sigma #C2139) in HBSS that had been supplemented with .5M 
EGTA and 1mM CaCl2. Digested livers were collected, filtered through a 100μm cell 
strainer, and centrifuged and washed several times at a low speed.  
Immunoblotting 
For in vivo insulin signaling studies, mice were fasted for 4hrs and injected with PBS or 
insulin (1IU/kg). 15 minutes after the injection, tissues were rapidly harvested. Tissues 
were homogenized in lysis buffer (20mM Hepes pH 7.4, 150mM NaCl, 2mM EDTA, 1% 
Triton X-100, .1% SDS, 10% Glycerol, .5% sodium deoxycholate) that had been 
supplemented with HALT protease and phosphatase inhibitors (Thermo Pierce). For 
Map4k4 expression analysis, tissues were homogenized in lysis buffer containing 
150mM NaCl, 2mM EDTA, and 2% SDS supplemented with protease and phosphatase 
inhibitors. Immunoblotting was performed using standard protocols. Membranes were 
blotted with the following antibodies: Akt (T308 #2965, S473 #3787, total #2920; Cell 
Signaling Technology) and Map4k4 (#A301-503A; Bethyl laboratories).  
Triglyceride (TG) extraction  
Livers were isolated from HFD-fed animals and frozen in liquid nitrogen. Hepatic TGs 
were extracted using the Folch method (297). Evaporated lipids were re-suspended in 1% 
Triton-X100 dissolved in isopropanol. TG content was determined using manufacturer’s 
protocol (Triglyceride Determination Kit, Sigma).  
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Flow cytometry 
The stromal vascular fraction (SVF) of the visceral adipose tissue (VAT) was isolated 
and weighed, and subsequent flow cytometry was performed as previously described 
(298). Briefly, VAT was minced in digestion buffer (5% BSA and 2mg/mL collagenase 
in HBSS) and incubated in a 37°C water-bath for 30-45 minutes. The digested tissue was 
passed through a 100μm cell strainer and centrifuged. The pelleted cells were collected as 
SVF and red-blood cells were lysed by incubation with red-blood cell lysis buffer. SVF 
cells were blocked in mouse IgG and counted. Antibodies used included F4/80 (APC, 
ABd serotec), CD11b (Percp 5.5, BD), and CD11c (V450, BD).  
Statistics 
Results are described as the mean ± SEM. Significance was assessed using a two-tailed 
Student’s t-test.   
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Results  
 
iMap4k4-KO mice display low fasting blood glucose levels and improved insulin 
responsiveness. 
To investigate the functional role of Map4k4 in whole-body glucose homeostasis, we 
deleted Map4k4 systemically. Since whole-body Map4k4-KO animals die at E9.5 due to 
failure of mesodermal cells to migrate away from the primitive streak (214), we 
generated Map4k4 floxed mice (bearing loxP sites around exon 7) with tamoxifen-
inducible UBC-cre ERT2 recombinase to inducibly delete Map4k4 in adult mice (Figure 
3.1, A). Tamoxifen was administered via intraperitoneal (IP) injection to both 
Map4k4flox/flox (control) and Map4k4-flox/flox-UBC-cre ERT2 (iMap4k4) mice (Figure 3.1, 
B). Tamoxifen induced cre recombinase activity and Map4k4 deletion in iMap4k4 mice, 
resulting in animals we denote as iMap4k4-KO mice. As expected, Map4k4 mRNA and 
protein expression was significantly reduced in iMap4k4-KO mice 18wks post-tamoxifen 
treatment in all of the tissues collected (Figure 3.1, C, D). Furthermore, both control and 
iMap4k4-KO mice continued to develop normally after tamoxifen treatment and did not 
display any obvious motor or behavioral defects (data not shown). These results indicate 
that Map4k4 is not required for adult mouse viability, and this inducible Map4k4 deletion 
mouse model can be used to address the metabolic functions of Map4k4 in obese 
animals. 
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Figure 3.1 Characterization of tamoxifen-inducible whole-body iMap4k4-KO mice.   
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Figure 3.1. Characterization of tamoxifen-inducible whole-body iMap4k4-KO 
mice. A. Schematic of alleles and transgenes used to inactivate Map4k4 systemically 
in adult tissues using tamoxifen. B. Schematic of experimental design. Both control 
(Map4k4flox/flox) and iMap4k4 (Map4k4-flox/flox-UBC-cre ERT2) mice were injected 
with tamoxifen as detailed in Materials and Methods to produce iMap4k4-KO mice. 
(C-D) Analysis was performed 18wks after first tamoxifen injection. C. Map4k4 
mRNA expression (N=6-10). D. Representative Map4k4 protein immunoblot with 
tubulin as loading control (N=6). (E) Body weight (g) of control and iMap4k4-KO 
mice were fed normal chow (ND) or high-fat diet (HFD) for 16wks starting 2wks 
after 1st tamoxifen injection (N= 16). (F-H) Both control and iMap4k4-KO mice were 
fed HFD for 16wks. F. Fat and lean mass analysis (N=4-6). G. Food intake (g/day) 
(N=4-6). H. Representative liver, skeletal muscle, and adipose tissue histology of 
HFD-fed mice stained for H&E. Arrows represent crown-like-structures and asterisk 
represents immune cells (N=6). Data represent the mean ± SEM (* P < 0.01, ** P < 
0.001, *** P < 0.0001).  
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To assess the role of Map4k4 in metabolic disease, animals were challenged with a lard-
based 60% high-fat diet (HFD). Animals with systemic Map4k4 deletion did not display 
body weight or adiposity differences compared to littermate controls (Map4k4flox/flox mice 
treated with tamoxifen) (Figure 3.1E, F). Consistent with this observation, both control 
and iMap4k4-KO mice consumed similar quantities of food (Figure 3.1, G). Furthermore, 
although no gross histological changes were observed in metabolic tissues (Figure 3.1, 
H), the visceral adipose tissue (VAT) displayed a slight reduction in macrophage content 
as assessed by histology (Figure 3.1, H), RT-qPCR (Figure 3.2, A), and flow cytometry 
(Figure 3.2, B-E). Interestingly, despite similar adiposity, HFD-fed iMap4k4-KO animals 
showed enhanced whole-body insulin responsiveness as assessed by an insulin tolerance 
test (ITT) (Figure 3.3, A). Strikingly, the ITT curves of HFD-fed iMap4k4-KO mice 
overlapped with age-matched lean animals (Figure 3.3, A), suggesting that whole-body 
Map4k4 deficiency in obese animals improves peripheral insulin sensitivity to levels 
similar to those observed in lean controls. We also found that iMap4k4-KO mice had a 
significant 20% reduction in fasting glucose levels (Figure 3.3, B), as well as lower 
circulating insulin levels (Figure 3.3, C), consistent with increased insulin responsiveness 
in vivo. However, no detectable changes in glucose tolerance (GTT) were detected 
(Figure 3.3, B).  
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Figure 3.2. Systemic Map4k4 deletion reduces adipose tissue inflammation without 
changing adiposity.  
  
Figure 3.2. Systemic Map4k4 deletion reduces adipose tissue inflammation without 
changing adiposity. (A-E) Animals were fed HFD for 16wks and visceral adipose tissue 
was isolated. A. Relative mRNA expression of various inflammatory genes as indicated 
(N=7). B. VAT stromal vascular fraction was isolated and FACs analysis performed. 
Representative FACs scatter plot is shown. Left panel shows control mice and right 
panel iMap4k4-KO mice. Upper panel shows F4/80 and CD11b positive cells while 
lower panel shows CD11b and CD11c positive cells (N=10-13). C. Number of 
macrophages (F4/80-positive cells) per mg of VAT (N=10-13). D. Percentage of CD11c-
positive cells (N=10-13). E. CD11c-positive cells per mg of VAT. (N=10-13). Data 
represent average mean ± SEM (* P < 0.05, ** P < 0.005).  
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As an additional assessment of insulin sensitivity on a cellular level, we measured insulin 
signaling in adipose tissue, liver, and muscle following a bolus insulin injection into 
HFD-fed animals. Consistent with enhanced whole-body insulin responsiveness, 
iMap4k4-KO mice showed significant improvements in insulin-induced Akt 
phosphorylation (at Ser473 and Thr308) in the liver and in the VAT (Figure 3.3 D, E). 
These data indicate that iMap4k4-KO mice are protected from obesity-induced insulin 
resistance at least in part by enhancing insulin signaling to Akt in adipose tissue and liver. 
Because obesity leads to glucose intolerance and insulin resistance in various organs 
including adipose tissue, liver, and skeletal muscle, we aimed to identify the contribution 
of Map4k4 in each of these tissues to affect whole-body glucose homeostasis and insulin 
sensitivity.   
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Figure 3.3 Systemic Map4k4 deletion ameliorates obesity-induced metabolic 
dysfunction and enhances insulin signaling in adipose and liver.  
  
Figure 3.3 Systemic Map4k4 deletion ameliorates obesity-induced metabolic 
dysfunction and enhances insulin signaling in adipose and liver. (A-B). Control and 
iMap4k4-KO mice were fed ND or HFD for 16wks. A. Percentage of basal glucose 
remaining during insulin tolerance test (ITT) (N=7-17). B. Blood glucose levels during 
glucose tolerance test (GTT) (N=10-17). C. Fasting insulin levels in HFD-fed mice 
(N=13). D. Representative protein immunoblots of Akt signaling (total, thr308, ser473) in 
liver, adipose tissue and skeletal muscle 15 minutes after PBS or insulin injection in 
HFD-fed animals as described in Materials and Methods. E. Densitometry analyses of D 
(N=6-10). Results are the mean ± SEM  (* P < 0.05, ** P < 0.005, *** P < 0.0005).   
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Adipose Map4k4 does not influence whole-body glucose homeostasis. 
 Obesity-induced adipose tissue dysfunction – including adipose tissue inflammation, 
altered adipokine secretion and reduced lipid-buffering capacity – contribute to the 
development of whole-body insulin resistance (55, 56, 100-102). Since Map4k4 
expression is elevated in obese human adipose tissue (271) and studies performed in vitro 
suggest Map4k4 is a negative regulator of insulin action (212, 236), we aimed to 
specifically ablate Map4k4 expression in adipocytes by crossing Map4k4flox/flox mice to 
Adiponectin-cre transgenic mice (Figure 3.4, A). As controls, Map4k4flox/flox littermates 
that do not express cre recombinase were used. The resulting adipose-specific knockout 
(Ad-Map4k4-KO) mice displayed disrupted Map4k4 expression in adipocyte fractions of 
all the adipose tissue depots examined (visceral, subcutaneous, and brown adipose) but 
not in the spleen or the heart (Figure 3.4, B-C). Isolated adipocytes were used to confirm 
Map4k4 depletion as the adipose tissue is composed of various cell types including 
immune cells, pre-adipocytes, and the vasculature that could contribute to Map4k4 
expression in whole tissue. To test whether the enhanced insulin sensitivity previously 
observed in obese iMap4k4-KO mice was mediated by the actions of Map4k4 in adipose 
tissue, animals were challenged with a HFD for 16wks. Ad-Map4k4-KO animals 
developed normally and gained similar weight and fat mass as control littermates fed ND 
or HFD (Figure 3.4 D-F). To assess whether Ad-Map4k4-KO mice displayed altered FA 
release, which might impact glucose metabolism, non-esterified fatty-acid (NEFA) levels 
were measured under basal conditions and post-β3-adrenergic stimuli (IP injection of CL 
316,243). As expected, NEFA levels were increased following CL 316,243 injection; 
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however, both control and Ad-Map4k4-KO mice displayed comparable plasma NEFA 
levels (Figure 3.4, G). Metabolic function as assessed by glucose tolerance (GTT) and 
insulin sensitivity (ITT) was also similar between control and Ad-Map4k4-KO mice fed 
ND or HFD (Figure 3.4, H-I). Consistent with the lack of metabolic changes, control and 
Ad-Map4k4-KO mice displayed similar fasting insulin levels (Figure 3.4, J). 
Furthermore, inflammation in both subcutaneous and visceral adipose tissue as assessed 
by histology (Figure 3.4, K) and RT-qPCR (Figure 3.4 L-M) was also similar between 
groups. Overall, these results indicate that loss of Map4k4 in adipocytes does not alter the 
adipose functions tested or whole-body glucose metabolism and suggest that the 
improved adipose insulin sensitivity observed in iMap4k4-KO mice is not mediated by 
the actions of Map4k4 in the adipose tissues. 
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Figure 3.4. Adipose-specific Map4k4 deletion in mice does not alter systemic glucose 
tolerance or insulin responsiveness.  
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Figure 3.4. Adipose-specific Map4k4 deletion in mice does not alter 
systemic glucose tolerance or insulin responsiveness. A. Schematic of alleles 
and transgenes used to inactivate Map4k4 in the adipose using adiponectin-cre 
transgene. B. Relative Map4k4 mRNA expression in adipose tissues, spleen, 
and heart (N=4). C. Relative Map4k4 mRNA expression in isolated adipocytes 
from visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and 
brown adipose tissue (BAT) (N=3). (D-M) Control and Ad-Map4k4-KO mice 
were fed ND or HFD for 16wks. D. Body weight (g) (N=8-14). E. SAT mass 
relative to body weight (N=5). F. VAT mass relative to body weight (N=5). G. 
NEFA levels in HFD-fed mice before and after 1hr CL 316,243 IP injection 
(N=5). H. GTT (N=10-15). I. ITT (N=10-15). J. Fasting insulin levels (N=5-6). 
K. Representative histology of VAT and SAT in HFD-fed mice. Slides were 
stained with H&E (N=10). Arrows represent crown-like-structures and asterisks 
represent immune cell infiltration (L-M) Relative mRNA of various 
inflammatory genes assessed in VAT (L) (N=6-8) and SAT (M) (N=6-8). 
Results are the mean ± SEM  (* P < 0.05, *** P < 0.0001).   
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Hepatocyte-specific Map4k4 deletion does not improve metabolic parameters in lean or 
obese mice. 
In the fed state, insulin suppresses glycogenolysis and gluconeogenesis while stimulating 
lipid synthesis in the liver; while in obesity-induced insulin resistance, insulin fails to 
suppress hepatic glucose production, thereby contributing to elevated blood glucose 
levels (299). To assess whether hepatic Map4k4 could account for the improved insulin 
sensitivity observed in the HFD-fed iMap4k4-KO mice, Map4k4flox/flox animals were 
crossed to mice expressing a cre transgene driven by the hepatocyte-specific albumin 
promoter (Figure 3.5, A). Map4k4flox/flox littermates that do not express cre recombinase 
were used as controls. Since the liver consists of several cell types including Kupffer 
cells, we isolated hepatocytes to confirm hepatocyte-specific deletion of Map4k4 in 
Map4k4flox/flox-Alb-cre (Alb-Map4k4-KO) mice (Figure 3.5, B-C). To assess whether 
hepatic Map4k4 contributed to whole-body glucose metabolism, control and Alb-
Map4k4-KO mice were challenged with a HFD for 16wks. Both control littermates and 
Alb-Map4k4-KO animals gained similar weight upon high-fat feeding (Figure 3.5, D-E), 
and fasting insulin and NEFA levels were unchanged between groups (Figure 3.5. F-G). 
Furthermore, no alterations in fasting glucose levels, pyruvate tolerance test (PTT), GTT, 
or ITT were observed among control and Alb-Map4k4-KO animals on ND or HFD 
(Figure 3.5, H-K). Although liver histology of Alb-Map4k4-KO mice revealed a slight 
increase in hepatic lipid accumulation compared to controls (Figure 3.5, L), this modest 
increase was not statistically significant as assessed by hepatic triglyceride content 
(Figure 3.5, M). These results indicate that hepatic Map4k4 depletion does not contribute 
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to the reduced basal glucose levels or improved insulin sensitivity observed upon 
inducible whole-body Map4k4 deficiency. 
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Figure 3.5. Hepatic Map4k4 does not contribute to systemic glucose tolerance or 
insulin responsiveness. 
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Figure 3.5. Hepatic Map4k4 does not contribute to systemic glucose tolerance or 
insulin responsiveness. A. Schematic of alleles and transgenes used to inactivate 
Map4k4 using albumin-cre transgene. B. Relative Map4k4 mRNA expression in liver, 
skeletal muscle, and adipose tissue (N=7-14). C. Relative Map4k4 mRNA expression in 
isolated hepatocytes (N=3). (D-M) Mice were fed ND or HFD for 16wks. D. Body 
weight (g) (N=6-13). E. Liver weight (g) (N=6-17). F. Fasting insulin levels (N=4-15). 
G. NEFA levels of HFD-fed mice (N=4-15). H. GTT (N=8-16). I. ITT (N=8-16). J. 
Blood glucose levels during pyruvate tolerance test (PTT) (N=7-16). K. Livers were 
isolated and RT-qPCR performed on the indicated genes of HFD-fed animals (N=5-7). L. 
Representative liver histology of HFD-fed mice. Slides were stained with H&E (N=10). 
M. Liver triglyceride extraction (TG/mg of liver) of HFD-fed mice (N=5-11). Results are 
the mean ± SEM (* P < 0.01, *** P < 0.0001).   
  63 
Map4k4 deletion in Myf5-positive cells results in improved metabolic parameters.  
Skeletal muscle plays a major role in regulating whole-body glucose metabolism and is 
responsible for the largest fraction of insulin-mediated glucose uptake from the blood. To 
determine whether Map4k4 in skeletal muscle affects whole-body metabolism, we 
crossed Map4k4flox/flox animals to mice that express cre recombinase under the control of 
the Myf5 promoter (Figure 3.6, A). Myf5-cre was used to delete Map4k4 in muscle 
precursors because previous reports from our laboratory have demonstrated that Map4k4 
plays a key role during early stages of muscle differentiation in C2C12 cells (234). As 
controls, we used Map4k4flox/flox littermates, which do not express cre recombinase. As 
expected, Map4k4 expression was diminished in several of the skeletal muscles collected 
(i.e., trapezius, triceps, and soleus) as well as brown adipose tissue (BAT), as Myf5 is 
expressed in muscle and BAT precursors (Figure 3.6, B) (300-302). Consistent with 
previous reports on Myf5 expression pattern, Map4k4 expression was not altered in the 
visceral adipose tissue (VAT) (Figure 3.6, B) (300-302). When challenged with a HFD, 
both control and Map4k4flox/flox-Myf5-cre (Myf5-Map4k4-KO) mice gained weight, 
although the Myf5-Map4k4-KO animals trended to be smaller (Figure 3.6, C). Whole-
body lean and fat mass analysis, however, did not reveal any statistical differences 
between control and Myf5-Map4k4-KO mice as measured by 1H-MRS (Figure 3.6, D) or 
individual tissue weights (Figure 3.6, E-F). Furthermore, energy metabolism as assessed 
by food intake (Figure 3.6, G), oxygen consumption (Figure 3.6, H), carbon dioxide 
production (Figure 3.6, I), energy expenditure (Figure 3.6, J), and physical activity levels 
(Figure 3.6, K) were not statistically different between groups. Fasting insulin and NEFA 
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levels were also unchanged in Myf5-Map4k4-KO mice compared to control mice (Figure 
3.6, L-M). Strikingly, however, despite similar adiposity, HFD-fed Myf5-Map4k4-KO 
animals displayed decreased fasting glucose levels and improved glucose clearance 
during a GTT, suggesting Myf5-Map4k4-KO mice were more glucose tolerant than 
controls (Figure 3.6, N). We then performed an ITT, and consistent with enhanced 
glucose tolerance, Myf5-Map4k4-KO mice were significantly more insulin sensitive 
compared to controls (Figure 3.6, O-P). These results suggest that Map4k4 deletion in 
Myf5-positive cells recapitulates in large part the metabolic benefits observed in HFD-
fed iMap4k4-KO mice, and demonstrate that Map4k4 in Myf5-positive cells promotes 
obesity-induced metabolic dysfunction.  
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Figure 3.6. Map4k4 deletion in Myf5-positive tissues improves glucose tolerance and 
insulin responsiveness. 
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Figure 3.6. Map4k4 deletion in Myf5-positive tissues improves glucose tolerance and 
insulin responsiveness. A. Schematic of alleles and transgenes used to inactivate 
Map4k4 using Myf5-cre knockin allele. B. Relative Map4k4 mRNA expression in 
various muscles, adipose tissues, and liver (N=5). C. Body weight (g) of ND and HFD-
fed mice (N=7-18). D. Fat and lean mass (g) analysis using 1H-MRS of HFD-fed mice 
(N= 5). E. Adipose tissues relative to body weight in ND-fed mice. Visceral adipose 
tissue (VAT), inguinal subcutaneous adipose tissue (iWAT), axial subcutaneous adipose 
tissue (aWAT), perirenal adipose tissue (pWAT) and brown adipose tissue (BAT) (N=8). 
F. Muscle weight relative to body weight in ND-fed mice (N=8). (G-M) Mice were fed 
HFD for 8wks. G. Food intake (g/day) (N=5). H. Oxygen consumption rate (VO2) (N=5). 
I. Carbon dioxide production rate (VCO2) (N=5). J. Energy expenditure (N=5). K. Total 
activity levels (N=5). L. Fasting insulin levels of  (N=6-8). M. Fasting NEFA levels 
(N=5). N. GTT (N=7-17). O. ITT of ND-fed animals (N=11-19). P. ITT of HFD-fed 
animals (N=7-13). Results are the mean ± SEM (* P < 0.05, ** P < 0.005).   
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To further assess peripheral insulin sensitivity in the Myf5-Map4k4-KO mice, HFD-fed 
control and Myf5-Map4k4-KO animals were injected with PBS or insulin, followed by 
collection of liver, adipose tissue, and skeletal muscle samples. Myf5-Map4k4-KO mice 
displayed a modest increase in Akt phosphorylation in response to insulin in the soleus 
muscle, a tissue with near-complete Map4k4 ablation, and no changes in Akt 
phosphorylation in the liver (Figure 3.7, A-B). Surprisingly, Myf5-Map4k4-KO mice 
displayed a striking enhancement of Akt phosphorylation in the VAT (Figure 3.7, A-B), a 
tissue that expressed normal Map4k4 levels in these mice (Figure 3.6, B). No gross 
morphological changes were observed in either skeletal muscle or VAT that could 
explain improved whole-body insulin action (Figure 3.7, C), and both groups of mice 
displayed similar adipose tissue inflammation profiles as assessed by histology and 
inflammatory marker gene expression (Figure 3.7, C-D). We also measured the gene 
expression and total circulating levels of muscle-secreted factors (myokines) including 
Fgf-21, IL-6, and Irisin and found no differences between control and Myf5-Map4k4-KO 
mice (Figure 3.7, E-H). These results demonstrate that Map4k4 deletion in Myf5-positive 
tissues protects mice from obesity-induced glucose intolerance and insulin resistance and 
this protection may be mediated in part via an indirect effect on the visceral adipose 
tissue. 
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Figure 3.7. Map4k4 deletion in Myf-5-positive tissues improves insulin signaling in 
visceral adipose tissue.  
Figure 3.7. Map4k4 deletion in Myf-5-positive tissues improves insulin signaling in 
visceral adipose tissue. (A-H) Animals were fed ND or HFD for 8wks. A. 
Representative protein immunoblot of Akt signaling in liver, skeletal muscle and VAT in 
response to a bolus insulin injection (1U/kg) as described in Materials and Methods.  B. 
Densitometry analysis of A (N=6-7). C. Representative skeletal muscle (soleus) and VAT 
histology of HFD-fed control and Myf5-Map4k4-KO mice. Slides were stained with 
H&E (N=10). D. VAT was isolated and RT-qPCR performed on the indicated genes of 
HFD-fed animals (N=6-12). E. Gene expression of various myokines in skeletal muscle 
(soleus) (N=7-14). (F-H) Circulating levels of Fgf-21 (F), IL-6 (G), and Irisin (H). 
Results are the mean ± SEM (* P < 0.05, ** P < 0.005, *** P < 0.0001).  
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Taken together, the data obtained from our four Map4k4 knockout mouse models 
presented here suggest that the metabolic improvements observed in iMap4k4-KO mice 
may be due primarily to the actions of Map4k4 in cells derived from Myf5-positive 
skeletal muscle cells and not to the actions of Map4k4 expressed in adipose cells or 
hepatocytes. Since Ad-Map4k4-KO animals (which also induce Map4k4 deletion in 
BAT) do not display any metabolic changes, skeletal muscle rather than BAT is more 
likely responsible for the metabolic improvements observed in Myf5-Map4k4-KO mice. 
Furthermore, these data suggest there is physiological cross-talk between Myf5-positive 
cells and the visceral adipose tissue that contributes to obesity-induced insulin resistance, 
and Map4k4 may be an important key regulator of this cross-talk.  
Discussion  
 
The results presented here demonstrate a role for Map4k4 in promoting obesity-induced 
insulin resistance, suggesting Map4k4 as a novel potential therapeutic target for the 
treatment of T2D. Induced systemic Map4k4 deficiency improves metabolic health in 
obese mice by lowering fasting glucose levels and improving insulin sensitivity (Figure 
3.3). While this beneficial effect of systemic Map4k4 deletion in mature mice is 
associated with enhanced insulin signaling to Akt in adipose tissue and liver (Figure 3.3), 
conditional KO mice with selective Map4k4 deletion either in adipose tissue depots 
(Figure 3.4) or in liver (Figure 3.5) display no overt metabolic phenotypes. Rather, 
Map4k4 deficiency in Myf5-positive cells, including all skeletal muscles, largely 
recapitulates the effects observed in inducible whole-body Map4k4-ablated mice, 
improving metabolic functions in the obese state (Figure 3.6). Surprisingly, Map4k4 
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deletion in Myf5-positive cells causes enhancement of insulin signaling to Akt in VAT 
(Figure 3.7), a tissue that is nearly devoid of Myf5 expression (303), indicating 
interesting inter-tissue signaling between Map4k4 deficient Myf5-positive cells and white 
adipocytes. 
 
Employing iMap4k4-KO mice, we bypassed the embryonic lethality observed in 
constitutive Map4k4-null mice (214) and found that Map4k4 is not essential for adult 
viability. Indeed, the iMap4k4-KO mice presented here did not display obvious 
behavioral defects and continued to gain weight throughout the study (Figure 3.1, E-F). 
Furthermore, despite similar adiposity, inducible systemic Map4k4 deletion enhances 
whole-body insulin action via improved adipose and liver insulin sensitivity (Figure 3.3, 
A, D-E). Interestingly, iMap4k4-KO mice displayed slightly reduced adipose tissue 
inflammation (Figure 3.2); consistent with previous data showing Map4k4 silencing in 
macrophages in vivo dampens inflammation in lean mice (231). Future studies using 
conditional Map4k4 deletion in macrophages will be required to assess the role of 
Map4k4 in immune cells in metabolic disease.  
 
Previous reports have shown that enhanced peripheral insulin sensitivity can be 
associated with lowered insulin levels, as less insulin is needed to clear glucose from the 
circulation (304-306). Consistent with these reports, iMap4k4-KO mice displayed 
reduced insulin levels compared to controls (Figure 3.3, C). However, although obese 
iMap4k4-KO mice were more insulin sensitive and displayed lower fasting glucose levels 
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compared to controls (Figure 3.3, A-B), no changes in glucose clearance were detected  
(Figure 3.3, B). We hypothesize that the reduced insulin levels in the iMap4k4-KO mice 
are at least in part secondary to enhanced peripheral insulin sensitivity.  However, lower 
insulin levels could also explain improvements in whole-body insulin action with 
minimal changes in glucose tolerance. Thus, these results are not inconsistent with the 
notion that Map4k4 plays a role in pancreatic β-cell function, potentially promoting 
insulin secretion in the obese state. Additional studies will be required to address a 
possible role for Map4k4 in pancreatic β-cell function in vivo.  
 
Using Myf5-cre mice to deplete Map4k4 in skeletal muscle, we found that despite equal 
adiposity (Figure 3.6, C-E), Myf5-Map4k4-KO mice were resistant to obesity-induced 
metabolic dysfunction (Figure 3.6, N, P). Because previous work from our laboratory 
suggested Map4k4 is highly expressed in satellite cells and may play a role during early 
stages of muscle differentiation (234), we selected a cre recombinase driven by a 
promoter that is expressed during this time frame (307-309). However, skeletal muscle 
weights (Figure 3.6, F) and histology results (Figure 3.7. C) appear normal in Myf5-
Map4k4-KO mice, suggesting no changes in muscle development. Although recent 
studies indicate that Myf5 is also expressed in certain adipose tissue depots (300-302), we 
hypothesize that Myf5-expressing myocytes and not brown adipose cells mediate the 
metabolic effects observed in Myf5-Map4k4-KO mice, as Ad-Map4k4-KO animals, 
which also delete in the BAT, do not display any improvements in metabolic function 
(Figure 3.4).  
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Map4k4 deletion in the Myf5-positive tissues largely recapitulates the improved 
metabolic effects observed upon systemic Map4k4 ablation, protecting mice from 
obesity-induced metabolic dysfunction. Although both iMap4k4-KO and Myf5-Map4k4-
KO mice display enhanced whole-body insulin action and reduced fasting glucose levels 
(Figure 3.3, 3.6), glucose clearance was not altered in iMap4k4-KO mice (Figure 3.3, B). 
Since iMap4k4-KO mice deplete Map4k4 systemically, this discrepancy between models 
may be due to a potential role of Map4k4 in the pancreas, which is only observed in 
iMap4k4-KO mice. Consistent with this hypothesis, iMap4k4-KO mice display reduced 
fasting insulin levels (Figure 3.3, C), whereas Myf5-Map4k4-KO mice do not. Both 
models, however, display improved peripheral insulin sensitivity in association with 
enhanced insulin signaling to Akt in VAT (Figure 3.3, D-E, and Figure 3.7, A-B) and 
these data are consistent with previous studies that show silencing Map4k4 expression 
prevents cytokine-induced insulin resistance (232). 
 
Because Myf5-Map4k4-KO mice display improved insulin sensitivity in the VAT (Figure 
3.7, A-B), a tissue that does not show Map4k4 deletion (Figure 3.6, B), Map4k4 ablation 
in Myf5-positive cells apparently impacts Myf5-negative tissues. This observation 
suggests that Map4k4 could regulate production or activity of an as yet unidentified 
factor (or factors) that in turn influences adipose tissue insulin sensitivity. Several 
muscle-derived mediators have been identified including Fgf-21, IL-6, and Irisin (207). 
Fgf-21 and IL-6 are mostly secreted from other tissues including the liver during fasting 
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conditions (Fgf-21) and immune cells during an inflammatory response (IL-6) (207). We 
measured relative gene expression and circulating levels of these two secreted factors and 
found no statistical differences between control and Myf5-Map4k4 KO mice (Figure 3.7, 
E-G). Furthermore, although highly controversial, Irisin circulating levels have been 
reported to increase after exercise and induce a white-to-brown shift in adipocytes (209). 
We do not observe any gene expression changes or circulating levels of Irisin in our mice 
(Figure 3.7, E, H). Thus, future studies will aim to identify the circulating factor(s) that 
improve insulin sensitivity in Myf5-Map4k4 KO mice.   
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Chapter IV: Concluding remarks and future directions 
Adipose dysfunction links obesity to insulin resistance (56). Therefore, our laboratory is 
interested in identifying novel regulators of adipocyte function, as these signaling 
pathways can contribute to the maintenance of healthy systemic glucose metabolism. One 
of these potential regulators of adipocyte function is Map4k4, a protein kinase identified 
by previous colleagues in the Czech laboratory as a negative regulator of insulin action 
and glucose transport (212). The work presented here asked the following questions: 
Does Map4k4 regulate other adipocyte functions besides glucose transport? If so, 
what are the mechanisms? Given than Map4k4 is a pro-inflammatory protein kinase 
(231) and its expression increases during obesity (data not shown), what is the effect of 
systemic Map4k4 depletion on metabolic disease?  
 
To answer the first question, I used 14C-tracing experiments in cultured 3T3-L1 
adipocytes to measure lipid synthesis, an important adipocyte function. Specifically, I 
used 14C-glucose and 14C-acetate separately as tracers to measure overall lipid synthesis 
(using glucose) and de novo lipogenesis (using acetate) by determining the amount of 
radiolabel incorporation in the neutral lipid fraction (triglycerides). My results indicated 
that Map4k4 depletion using siRNA results in increased radiolabel (both glucose and 
acetate) incorporation into triglycerides. Furthermore, Map4k4 overexpression resulted in 
decreased 14C-glucose incorporation into triglycerides. After establishing a role of 
Map4k4 as a repressor of lipid synthesis, I assessed the mechanism by which Map4k4 
repressed this process. Using gain- and loss-of-function approaches, I determined that 
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unlike previous published studies, Map4k4 is not necessary or required for Jnk signaling 
and Map4k4 does not signal via Jnk to repress lipid synthesis. A previous colleague in the 
Czech laboratory reported that Map4k4 represses mTORC1 (261). Consistent with these 
findings, depletion of Map4k4 using siRNA enhances mTORC1 signaling as assessed by 
increases in phospho-S6 and phospho-4E-bp1 proteins. Furthermore, when mTORC1 
function was inhibited using rapamycin, the increases in lipid synthesis observed with 
Map4k4 depletion were abolished, confirming the involvement of mTORC1. I also tested 
the expression of Srebp-1, a major lipogenic transcription factor that is a downstream 
target of mTORC1, and found that both protein and mRNA expression of Srebp-1 was 
elevated upon Map4k4 depletion. Furthermore, depletion of Srebp-1 using siRNA 
abolishes the effects on lipid synthesis observed upon Map4k4 depletion.  
 
To answer the second question, I used a tamoxifen-inducible cre/ER system to inducibly 
delete Map4k4 globally in adult mice. Post-tamoxifen treatments, both control and 
iMap4k4-KO mice were fed a high-fat diet to promote obesity and metabolic disease. 
Using standard measures of metabolic function (glucose tolerance tests, insulin tolerance 
tests, plasma insulin and NEFA levels, and in vivo peripheral insulin sensitivity), I 
established that Map4k4 represses insulin sensitivity. To determine the role of Map4k4 in 
insulin-responsive tissues (skeletal muscle, adipose tissue, and liver), I used conditional 
knockout mouse models to deplete Map4k4 in each of these tissues and assessed 
metabolic parameters. I found that only deletion of Map4k4 in Myf5-positive cells, which 
include skeletal muscle, recapitulates the metabolic effects observed in global inducible 
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Map4k4 deleted mice. Furthermore, although both hepatic-Map4k4 KO mice and 
adipose-Map4k4 KO mice display slight enhancements in lipid synthesis, these effects do 
not alter metabolic disease.   
In summary, the data in this thesis furthers our understanding of the functions of the 
protein kinase Map4k4 in regulating whole-body metabolism and provide support for the 
notion that Map4k4 targeting could prove beneficial in the treatment of metabolic 
disease. In trying to understand the role of Map4k4 in vivo, we utilized a tamoxifen-
inducible system to ubiquitously deplete Map4k4 in mature mice (Figure 3.1, A). Using 
this model, we found that global Map4k4 depletion (iMap4k4-KO mice) ameliorates 
obesity-induced metabolic dysfunction by improving whole-body insulin action and 
reducing fasting hyperglycemia (Chapter III). Interestingly, these effects are associated 
with enhanced insulin signaling to Akt in adipose tissue and liver (Figure 3.3). Thus, to 
assess the role of Map4k4 in metabolic tissues responsible for glucose regulation –the 
adipose tissue, the liver, and the skeletal muscle – we employed tissue-specific knockout 
models to deplete Map4k4 specifically in these tissues. Based on our findings that 
Map4k4 suppresses glucose transport and lipid synthesis in cultured adipocytes (Chapter 
II), we were surprised to find that Map4k4-specific adipose knockout mice did not alter 
any metabolic parameters tested (Figure 3.4). Similarly, although systemic Map4k4 
depletion is also associated with enhanced insulin signaling in the liver, liver-specific 
Map4k4 knockout mice did not result in improved metabolic phenotypes (Figure 3.5). 
Interestingly, Map4k4 depletion in Myf5-positive tissues, which include all skeletal 
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muscles tested, recapitulates the metabolic benefits observed with global Map4k4 
depletion, ameliorating obesity-induced metabolic dysfunction and enhancing insulin 
signaling to Akt in the adipose tissue. Thus, our current view is that Map4k4 in Myf5-
positive tissues suppresses systemic insulin sensitivity (Figure 4.1).  
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Figure 4.1. Schematic representation of Map4k4 action in Myf5-positive cells.  
Figure 4.1. Schematic representation of Map4k4 action in Myf5-positive cells. 
Map4k4 deletion in Myf5-cells, including all skeletal muscles, improves insulin signaling 
to Akt in the Visceral adipose tissue (VAT) to alter whole-body glucose homeostasis.  
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Map4k4 as a negative regulator of lipid synthesis  
 
This section will address my interpretations and potential pitfalls of the studies presented 
in Chapter II. Previous colleagues in the Czech lab discovered Map4k4 in a siRNA-
screen as a negative regulator of insulin-stimulated glucose transport in adipocytes 
(Figure 1.5, A) (212). In Chapter II, I further determined that Map4k4 also represses 
another important adipocyte function, lipid synthesis, and these effects are independent of 
glucose transport (Figure 2.2, D-E). I concluded that Map4k4 is a negative regulator of 
lipid synthesis based on tracing studies using 14C-glucose incorporation into triglycerides 
in adipocytes that either overexpressed Map4k4 or were depleted of Map4k4. 
Furthermore, I determined that these effects were independent of glucose transport 
because tracing studies performed with 14C-acetate (which bypasses glucose transport) 
also show enhanced radiolabel incorporation in the triglyceride fraction upon Map4k4 
depletion. Therefore, I interpreted these results to suggest that Map4k4 is a negative 
regulator of lipid synthesis in cultured adipocytes and these effects are independent of 
glucose transport. Although the published studies that identified Map4k4 as a negative 
regulator of glucose transport using siRNA were not performed by me, a potential caveat 
of these studies is that Map4k4 does not directly affect glucose transport but rather 
Map4k4 affects the actin cytoskeleton, which in turn affects glucose transport. This is 
highly speculative and thus, future experiments addressing the role of Map4k4 in the 
cytoskeleton needs to be tested.  
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 As a Ste20-like kinase, Map4k4 is predicted to regulate Jnk signaling, and prior 
publications reported this to be the case (267-269). Since both Map4k4 and Jnk are pro-
inflammatory kinases (310), we hypothesized that depletion of Map4k4 would suppress 
the Jnk signaling cascade and promote lipid synthesis. Surprisingly, however, while 
Map4k4 depletion enhanced lipid synthesis as assessed by 14C-acetate incorporation into 
neutral lipids (triglycerides), Jnk depletion using siRNA suppressed this process (Figure 
2.3). In other words, mature adipocytes transfected with Map4k4 siRNA displayed an 
increase in radiolabel incorporation in lipids, while adipocytes transfected with Jnk 
siRNA displayed a decrease in radiolabel incorporation compared to control siRNA 
treated cells, suggesting Map4k4 and Jnk regulate lipogenesis in opposite manners 
(Figure 2.3). These results were surprising because 1) Map4k4 is published to be a 
positive regulator of the Jnk signaling cascade and 2) as a pro-inflammatory kinase, I 
predicted Jnk would repress lipid synthesis and thus behave like Map4k4. To test whether 
I could repeat previously published experiments that suggest Map4k4 is a positive 
regulator of Jnk, I used gain- and loss-of-function studies to measure endogenous Jnk 
signaling both at the protein level (Figure 2.4) as well as the mRNA expression of 
downstream targets (Figure 2.4). Overall, I did not find any evidence to suggest Map4k4 
affects Jnk activation in cultured adipocytes (Figure 2.4), fibroblasts, or HEK-293T cells 
(data not shown). However, when both Map4k4 and Jnk are ectopically overexpressed, as 
was previously published (267-269), I did observe increased Jnk activity (Figure 2.5). I 
interpreted these results to suggest that Map4k4 is not an endogenous Jnk activator and 
that the observed activation of Jnk by Map4k4 is an artifact of overexpression. Thus, 
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studies in which biological functions of Map4k4 have been attributed to Jnk signaling 
should be re-evaluated, as these results demonstrate that Map4k4 acts in a Jnk-
independent manner.  Future studies addressing bona fide direct Map4k4 targets will thus 
be highly informative.   
 
I next assessed the Ampk signaling pathway because Map4k4 has been suggested to 
promote Ampk signaling and repress mTORC1 activation (261, 282). As a catabolic 
signaling pathway, Ampk inhibits energy demanding processes, including lipid synthesis, 
by inhibiting mTORC1 and Acc (311). On the other hand, as a major anabolic-signaling 
node, mTORC1 promotes energy-demanding processes, including lipid synthesis, in an 
Srebp-1-dependent manner (42). Using gain- and loss-of-function studies where Map4k4 
expression was modulated, I probed the endogenous Ampk signaling pathway with 
various stimuli (including phenformin, glucose withdrawal, and oligomycin). While 
Map4k4 depletion significantly attenuated Ampk signaling as assessed by lower 
phospho-Acc and phospho-Ampk protein levels, Map4k4 overexpression increased 
phospho-Ampk. I interpreted these results to suggest that Map4k4 is a positive regulator 
of Ampk signaling (Figure 2.10). I next tested the Map4k4-mediated effects on 
downstream targets of the Ampk signaling pathway, specifically I tested whether Map4k4 
modulated mTORC1 and Srebp-1 activation to affect lipid synthesis. Consistent with 
previous results, I found that Map4k4 depletion enhanced mTORC1 signaling as assessed 
by increased phospho-S6 and phospho-4E-bp1 (Figure 2.6) (261). I also found that 
Map4k4 depletion using siRNA or using a kinase-dead Map4k4 adenovirus results in 
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increased total and cleaved Srebp-1 protein levels (Figure 2.7). To show Map4k4 
depletion requires this increase in mTORC1 signaling and Srebp-1 expression to increase 
lipid synthesis, I depleted Map4k4 in mature adipocytes using siRNA, blocked mTORC1 
signaling using rapamycin and measured the incorporation of 14C-glucose into 
triglycerides (Figure 2.6). These experiments showed that when mTORC1 signaling is 
inhibited, Map4k4 depletion no longer enhances lipid synthesis (Figure 2.6). One 
important caveat of this experiment is that the chronic rapamycin treatment (48hr) could 
also affect mTORC2. However, phospho-Akt (serine 473) protein immunoblots (a well-
known mTORC2 target) are not altered under these conditions (Figure 2.6 A), suggesting 
mTORC2 signaling is not affected. Furthermore, I depleted Map4k4 and Srebp-1 using 
siRNA (together and separately) and assessed the effects on lipid synthesis using 14C-
glucose incorporation into triglycerides (Figure 2.9). Similar to the experiments using 
rapamycin, these experiments showed that Map4k4 depletion requires Srebp-1 expression 
to increase lipid synthesis, as less 14C-glucose incorporation into triglycerides was 
observed if Map4k4 and Srebp-1 were co-depleted (Figure 2.9). Overall, I interpreted 
these results to suggest that Map4k4 depletion requires both mTORC1 function and 
Srebp-1 expression to affect lipid synthesis. Although these results suggest that Map4k4 
suppresses lipid synthesis in an Ampk, mTORC1, and Srebp-1-dependent mechanism in 
cultured adipocytes, we still lack mechanistic details determining how Map4k4 affects 
these signaling pathways. Since Map4k4 is a protein kinase, I hypothesize that Map4k4 
alters the activity of substrates via direct phosphorylation events and these targets may in 
  83 
turn, directly inhibit Ampk/mTORC1/Srebp-1 to affect lipid synthesis. Thus, future 
studies aimed at identifying Map4k4 substrates will be highly informative.  
 
Obesity is paradoxically associated with a reduction in adipose lipid synthesis (105). 
Various animal models have suggested that enhanced adipose lipogenesis can have two 
important effects in whole-body metabolism: 1) enhanced adipose lipogenesis can be 
beneficial as the adipose sequesters lipids to prevent deleterious accumulation of these 
lipids in muscle and liver, and 2) adipose lipogenesis can generate endogenous lipid 
ligands that promote insulin sensitivity (158). Since obese and insulin resistant patients 
display reduced lipid synthesis that is associated with increased Map4k4 expression (105, 
271), and based on the data I presented in Chapter II on Map4k4 repressing lipid 
synthesis, I hypothesized that Map4k4 adipose-specific depletion would result in 
improved metabolic health in obese mice. I therefore interbred Map4k4 floxed mice to 
adiponecticn-cre transgenic mice to delete Map4k4 in adipocytes in vivo. I fed these mice 
a high-fat diet to induce metabolic disease and assessed the differences between control 
and adipose-Map4k4 KO mice. Adipose-specific Map4k4 knockout mice did not display 
any detectable metabolic changes in lean or obese states as assessed by various tests 
including GTT, ITT, and fasting insulin and NEFAs levels. (Figure 3.4). Thus, although 
ex vivo lipid synthesis is slightly enhanced in these animals (data not shown), consistent 
with the notion that Map4k4 represses lipid synthesis (Chapter II), impairment of insulin 
sensitivity in the obese state was not prevented, contrary to our initial hypothesis. One 
possibility that explains these results is that the magnitude of the increased lipid synthesis 
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mediated by Map4k4 deletion in vivo is insufficient to alter whole-body metabolism. It is 
important to realize that regulation of lipid synthesis in vivo is subject to complex inter-
organ endocrine control as well as conditions of changing nutrient flux (i.e. fasting vs 
feeding) that are not present in cell culture models. Furthermore, there may be 
redundancy in adipose tissue in vivo with other related Ste20 kinases such as Tnik and 
Mink, which would lessen the influence of Map4k4 deletion. Because of the lack of 
metabolic phenotypes in the adiponectin-cre (as well as albumin-cre model), I did not 
pursue further studies to verify whether Map4k4 impacts signaling pathways identified as 
targets in cultured cells (i.e. Ampk, mTORC1, and Srebp-1); however, this could be an 
area of interest in future studies.  
 
The metabolic functions of Map4k4 in vivo 
 
This section will address my interpretations, potential pitfalls, and future directions of the 
studies presented in Chapter III. In Chapter II (in vitro studies), I found that Map4k4 
repressed lipid synthesis in cultured adipocytes. These results were consistent with 
previous literature, which suggested that Map4k4 inhibits insulin action in adipocytes, 
myocytes, and β-cells (212, 232, 233). Since obesity is associated with insulin resistance 
and in vitro studies suggest Map4k4 inhibits insulin action (212, 232, 233), I sought to 
determine whether Map4k4 plays a role in metabolic disease. To do so, I interbred mice 
carrying Map4k4 floxed alleles to mice with an inducible cre recombinase that is 
expressed systemically. I chose this model for two reasons: 1) to bypass embryonic 
development as global Map4k4 knockout mice display embryonic lethality (214) and 2)  
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mimic the systemic inhibition of Map4k4 activity that would result from a small 
molecule inhibitor. I confirmed Map4k4 depletion by mRNA and protein expression in 
various tissues including adipose tissue, liver, and skeletal muscle (Figure 3.1). Using this 
model, I induced metabolic disease and assessed metabolic function using various 
metabolic tests including GTTs and ITTs. These experiments demonstrated that mice 
with inducible systemic Map4k4 depletion displayed improved insulin tolerance when 
obese (Figure 3.3). Furthermore, these results were associated with improved insulin 
signaling to Akt in the adipose tissue and the liver as assessed by enhanced phospho-Akt 
in these tissues (Figure 3.3). Based on these experiments, I concluded that systemic 
Map4k4 depletion is beneficial in the setting of metabolic disease.  
 
To further elucidate the role of Map4k4 in insulin-responsive tissues in the context of 
metabolic disease, I interbred Map4k4 floxed mice to either adiponectin-cre transgenics 
or albumin-cre transgenics to obtain tissue-specific knockout mice for the adipose tissue 
or the liver. These mice were challenged with a high-fat diet and metabolic tests were 
performed. However, neither adipose-Map4k4 KO mice nor liver-Map4k4 KO mice 
displayed any metabolic changes compared to appropriate controls (Figure 3.4 and Figure 
3.5). It should be noted that these metabolic tests were also performed using a 45% high 
fat diet (compared to 60% high fat diet) for various time points including 8wks, 16wks, 
and 20wks of high-fat diets with similar results (data not shown). Furthermore, liver-
specific Map4k4 depletion slightly enhanced hepatic steatosis, as was anticipated based 
on results described in Chapter II; however, this slight increase was neither statistically 
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significant nor sufficient to alter metabolic profiles of liver-Map4k4 knockout mice 
(Figure 3.5). I interpreted these results to suggest that the improved insulin signaling in 
the adipose tissue and the liver of iMap4k4-KO mice is not a cell autonomous effect and 
therefore, these results may be mediated by other resident cell types present in these 
tissues such as immune cells or a secreted factor may be altered in iMap4k4-KO mice 
enhancing insulin responsiveness in the adipose tissue and liver.  
 
Next, I interbred Map4k4 floxed mice to Myf5-cre mice to deplete Map4k4 in the 
skeletal muscle.. These animals were challenged with a high-fat diet and metabolic 
disease assessed. Based on significant improvements in glucose tolerance and insulin 
sensitivity (as assessed by GTTs and ITTs, respectively), I concluded that mice with 
Map4k4 deletion in Myf5-positive cells (i.e. skeletal muscle) displayed improvements in 
metabolic disease despite equal obesity. Because systemic inducible Map4k4 KO mice 
also displayed metabolic improvements despite equal obesity, I interpreted these results 
to suggest that Myf5-Map4k4 KO mice largely recapitulated the effects observed upon 
systemic Map4k4 ablation, ameliorating obesity-induced metabolic dysfunction (Figure 
3.6). I further assessed peripheral insulin sensitivity in Myf5-Map4k4 KO mice and 
observed a significant increase in insulin sensitivity in the visceral adipose tissue (VAT), but not in the liver or the skeletal muscle (Figure 3.7). Because VAT reportedly displays a low number of Myf5-positive cells (300-302) and Map4k4 expression in this tissue is not altered, I interpreted these results to suggest a 
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circulating factor(s) from Myf5-positive cells with Map4k4 deletion (i.e. skeletal muscle) affected Myf5-negative tissues (VAT) to improve whole-body metabolism.  
 There are several potential pitfalls with the Myf5-cre study. First, it has been reported that the Myf5 is expressed in muscle and adipose progenitors(300-302). Consistent with this literature, Map4k4 expression was depleted in skeletal muscles, BAT, and certain WAT depots (300, 302, 303). I chose this cre model because a previous colleague in the Czech laboratory reported that Map4k4 inhibits the early 
stages of muscle differentiation in C2C12 cells (234). Because adipose-Map4k4 KO mice did not show improvements in metabolic disease, I attributed the improvements in metabolic health observed in Myf5-Map4k4 KO mice to non-adipose Myf5-positive cells (i.e. skeletal muscle). To prove this, however, I need to interbreed Map4k4 floxed mice with skeletal-muscle specific KO mice (i.e. α-actin-cre or MCK-cre) and show similar improvements in metabolic disease.  
 Second, because Myf5-cre mice also potently deplete Map4k4 expression in the BAT, it could be postulated that the metabolic improvements in Myf5-Map4k4 KO mice are mediated by alternations in BAT. Since adipose-Map4k4 KO, which also display Map4k4 depletion in BAT, do not display any metabolic changes; and BAT histology 
and BAT-specific gene expression was unaltered in Myf5-Map4k4 KO mice (data not 
shown), I interpreted these results to suggest that the metabolic effects observed in the 
Myf5-Map4k4 KO mice are not mediated by effects of Map4k4 in BAT. However, to 
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confirm this conclusion, BAT-specific KO mice (i.e UCP1-Map4k4 KO mice) need to be 
tested. Alternatively, the BAT can be de-activated via denervation and the effects of Myf5-Map4k4 KO mice on metabolic disease tested. If my interpretation is correct that the BAT does not play a role in the metabolic phenotypes observed in Myf5-Map4k4 KO mice, then denervation of the BAT should not alter the metabolic benefits observed by Map4k4 deletion using Myf5-cre.  
 Third, because the VAT contains a low population of Myf5-positive cells (303) and Myf5-Map4k4 KO mice display increased insulin sensitivity in this tissue (Figure 3.7), I interpreted these results to suggest that there is communication between Myf5-positive Map4k4 KO cells and Myf5-negative cells, potentially via the secretion of as of yet unidentified factor(s). This unidentified secreted factor(s) could be secreted into the circulation to enhance insulin sensitivity in the adipose tissue. Another plausible hypothesis is that this communication occurs in the VAT via secretion of local factors within the adipose tissue that sensitizes the whole tissue to the effects of insulin. One way to prove a circulating factor is secreted into the circulation of Myf5-Map4k4 KO mice to enhance insulin sensitivity of the VAT is to perform a parabiosis experiment where a control mouse shares the circulatory system of a Myf5-Map4k4 KO mouse. If my interpretation is correct, I would expect to observe metabolic improvements in both control and Myf5-Map4k4 KO mice.  
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Although we have yet to find the identity of such factor, we hypothesize that such factor 
may directly or indirectly impact insulin signaling to Akt. For example, signaling 
downstream of such a factor could attenuate the activity of negative regulators of the 
insulin-signaling pathway such that Akt activation can be enhanced. Map4k4 has been 
previously shown to alter Signal transducer and activator of transcription 3 (Stat3) 
phosphorylation levels, resulting in reduced Stat3 transcriptional activity (215).  I have 
preliminary evidence to suggest that Stat3 is downregulated in VAT of Myf5-Map4k4 
KO mice. Thus, it is tempting to speculate that Stat3 downregulation potentiates insulin 
signaling to Akt in the adipose tissue as Stat3 is responsive to various growth factors and 
it drives the expression of Suppressor of cytokine signaling 3 (Socs3), a negative 
regulator of the insulin-signaling pathway (312). More work is needed to identify the 
secreted factor and its role in promoting insulin sensitivity in Myf5-negative adipose 
cells.   
 
The data presented in this thesis provide evidence for a role of Map4k4 in metabolic 
disease. Global Map4k4 suppression improves obesity-induced metabolic dysfunction by 
enhancing systemic insulin sensitivity and lowering fasting glucose levels (Figure 3.3). 
These results are mediated, at least in part, by Map4k4 signaling in Myf5-positive tissues, 
which include all skeletal muscles, and not by Map4k4 signaling in the adipose tissue or 
liver. Since Myf5-Map4k4 KO mice display significant improvements in obesity-induced 
metabolic disease (Figure 3.6) and enhanced insulin signaling to Akt in the adipose tissue 
(Figure 3.7), a tissue with few Myf5-progenitor cells, we have uncovered an interesting 
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cross-talk between Myf5-positive and Myf5-negative tissues that regulate systemic 
insulin sensitivity and Map4k4 signaling is essential in this process (Figure 3.7).  
 
In summary, there are three main implications from this thesis that have advanced the 
field: 
1) Both in vitro (Chapter II) and in vivo (Chapter III) studies presented in this thesis 
are entirely consistent with the notion that Map4k4 can have deleterious effects on 
insulin action in the context of inflammation and excess nutrient supply, both of 
which are important mediators of metabolic disease. These results are also in 
agreement with previously published in vitro studies from our laboratory as well 
as others (212, 231-233). Based on the results in Chapter II, I expected Map4k4 to 
inhibit insulin action via its effects on adipose lipid synthesis. I found that 
Map4k4 also inhibits the effects of insulin in vivo, however, this is apparently not 
mediated by increased lipid synthesis in the adipose tissue. Nonetheless, the 
beneficial metabolic effects of Map4k4 ablation in obese adult mice confirms the 
potential of Map4k4 as a valid target of therapies for metabolic disease.   
2) Results from Chapter III and Appendix I show that Map4k4 can have different 
tissue-specific roles in metabolic disease. For example, while Map4k4 represses 
whole-body glucose homeostasis in Myf5-positive cells, Map4k4 in the pancreas 
may be required for proper insulin secretion. Furthermore, in vivo studies strongly 
suggest a potentially novel crosstalk between skeletal muscle and adipose tissue. 
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Discovering the factor(s) responsible for this crosstalk as well as mechanisms of 
Map4k4 action in β-cells are likely to be fruitful areas of future research.  
3) Finally, although our understanding of Map4k4 signaling is as yet far from 
complete, work in this thesis has advanced this understanding in several ways. I 
have refuted the reported role of Map4k4 as a positive regulator of the Jnk 
signaling pathway. Furthermore, I have also revealed novel roles for Map4k4 in 
the regulation of Ampk and Srebp-1 in cultured adipocytes.   
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APPENDIX I: 
Map4k4 promotes obesity-induced hyperinsulinemia. 
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Introduction 
 
Proper glucose regulation is essential for mammalian survival; therefore, highly 
controlled inter-organ networks exist to achieve euglycemia (1). In the fed state, glucose 
is absorbed from ingested foods and delivered via blood circulation to all tissues. 
Pancreatic β-cells sense this glucose surge and, in turn, secrete insulin (68). Insulin 
signals to peripheral tissues to normalize glucose levels by promoting glucose uptake in 
the muscle and adipose tissue while suppressing hepatic glucose production (313). 
During fasting conditions, low glucose levels promote glucagon secretion from 
pancreatic α-cells (5). Glucagon normalizes glucose levels by signaling to the liver to 
promote glycogen breakdown and glucose production (5). Therefore, circulating glucose 
levels reflect a balance between hepatic glucose production and peripheral (adipose tissue 
and skeletal muscle) glucose uptake and utilization, and proper pancreatic endocrine 
function is essential in this regulation.   
 
Obesity can be associated with peripheral insulin resistance, whereby released insulin 
fails to promote skeletal muscle and adipose glucose uptake as well as suppress hepatic 
glucose production, resulting in hyperglycemic conditions (11). Hyperglycemia, in turn, 
induces a compensatory adaptation in the pancreas, which is manifested by an increase in 
β-cell mass and function, resulting in insulin hypersecretion to restore euglycemia (12, 
13). Obese and insulin resistant patients eventually display β-cell dysfunction and failure, 
resulting in type-2 diabetes (T2D) (12, 14). Therefore, T2D is a condition with reduced 
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peripheral insulin action and gradual β-cell loss, which accounts for a 60% decrease in β-
cell mass observed in type-2 diabetics (12).  
 
T2D currently affects 9% of the population worldwide, however its incidence is predicted 
to dramatically increase as T2D-predisposing conditions such as obesity and insulin 
resistance continue to rise (7). It is of paramount importance to therapeutically manage 
insulin resistance and T2D as these diseases are commonly linked to other deadly co-
morbidities including cardiovascular disease and certain cancers (7). Current therapies 
aim to suppress hepatic glucose production (metformin) or potentiate insulin secretion 
(insulin secretagogues), however further intervention is often required (15). Interestingly, 
recent evidence suggests that although insulin resistance-induced hyperinsulinemic 
conditions are required to restore euglycemia, they can be detrimental in further 
promoting adiposity and insulin resistance (17). Thus, peripheral insulin resistance 
promotes insulin hypersecretion and hyperinsulinemia, which in turn, can further promote 
insulin resistance, creating a vicious feed-forward cycle that results in T2D (17). Thus, 
drug therapies that simultaneously improve the underlying peripheral insulin resistance 
and lower hyperinsulinemic conditions would prove useful in developing therapies for 
T2D (17).  
 
In finding novel regulators of insulin action, our laboratory identified the protein kinase 
Map4k4 as a negative regulator of insulin-mediated glucose transport (212). Studies in 
vitro suggest Map4k4 inhibits metabolic function (220). In cultured adipocytes, Map4k4 
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represses glucose transport and lipid synthesis (Chapter II) (236); in muscle cells, 
Map4k4 promotes Tnf-α-induced insulin resistance (232); and in β-cells, Map4k4 
promotes Tnf-α inhibition of glucose-stimulated insulin secretion (GSIS) (233). Recent 
studies in vivo extend our understanding of Map4k4 and suggest Map4k4 regulates 
systemic insulin sensitivity (Chapter III). Inducible global Map4k4 depletion restores 
obesity-induced insulin resistance and improves fasting glucose levels (Chapter III, 
Figure 3.3). However, despite enhanced insulin sensitivity, inducible Map4k4 global 
knockouts do not display changes in glucose clearance (Chapter III, Figure 3.3). 
Furthermore, global Map4k4 knockout mice show a significant reduction in fasting 
insulin levels (Chapter III, Figure 3.3). We therefore aimed to assess the role of Map4k4 
in β-cell insulin secretion. These studies extend our understanding of the role of Map4k4 
in metabolic dysfunction and further suggest Map4k4 as a therapeutic target for 
metabolic disease.  
Materials and Methods 
 
Animal Studies 
All of the studies performed were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Massachusetts Medical School. Animals were 
maintained in a 12hr light/dark cycle. Map4k4flox/flox (control) and Map4k4-flox/flox-UBC-
cre ERT2 (iMap4k4) mice were fed standard chow (Lab diet 5P76) and injected with 30
μg tamoxifen/40g body weight dissolved in corn oil for 5 consecutive days. 2wks after 
the 1st tamoxifen injection, mice were fed high-fat diet (HFD) (12492i Harlan) for 16wks. 
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For in vivo insulin secretion, mice were fasted for 16hrs and IP injected with 1g/kg 
glucose dissolved in PBS. Blood samples were withdrawn from the tail vein before and 
30 minutes after glucose injection.  
RNA Isolation and RT-qPCR 
Total RNA was isolated from isolated islets using TriPure isolation reagent (Roche) and 
following manufacturer’s instructions. Isolated RNA was DNAse treated (DNA-free, Life 
Technologies), and cDNA was synthesized using iScript cDNA synthesis kit (BioRad). 
RT-qPCR was performed using iQ SybrGreen supermix. Primer sequences used are as 
follows: Rplp0 (5’–TCCAGGCTTTGGGCATCA–3’, 3’–
CTTTATCAGCTGCACATCACTCAGA–5’); Map4k4 (5’-
CATCTCCAGGGAAATCCTCAGG-3’, 3’-TTCTGTAGTCGTAAGTGGCGTCTG-5’); 
Insulin 1 (5’-CCATCAGCAAGCAGGTCATTG-3’, 3’-
TGTGTAGAAGAAGCCACGCTCC-5’); Insulin 2 (5’-
CAGAAACCATCAGCAAGCAGG-3’, 3’-TTGACAAAAGCCTGGGTGGG-5’); 
Glucagon (5’-GAGGAACCGGAACAACATTGC-3’, 3’-
GCAATGAATTCCTTTGCTGCC-5’); Glut2 (5’-TGCTGCTGGATAAATTCGCC-3’, 
3’-TCAGCAACCATGAACCAAGG-3’); MafA (5’-AGGAGGAGGTCATCCGACTG-
3’, 3’-CTTCTCGCTCTCCAGAATGTG-5’); MafB (5’-AGGACCTGTACTGGATGGC-
3’, 3’-CACTACGGAAGCCGTCGAAG-5’); Nkx6.1 (5’-
CTTCTGGCCCGGAGTGATG-3’, 3’-GGGTCTGGTGTGTTTTCTCTTC-5’); Pdx-1 
(5’-GAGGTGCTTACACAGCGGAA-3’, 3’-GGGGCCGGGAGATGTATTT-5’).  
Plasma analysis  
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Mice were fasted overnight (16hrs), and plasma was collected via the tail vein. Serum 
insulin, C-peptide, and glucagon measurements were performed using an Insulin ELISA 
kit (Millipore), C-peptide ELISA kit (ALPCO), and Glucagon ELISA kit (R&D systems) 
according to the manufacturer’s instructions.  
Histology  
Mouse pancreatic tissue was isolated, arranged in one block, and fixed in 10% formalin 
for 4hrs. Blocks were paraffin embedded, sectioned, and stained with hematoxylin and 
eosin (H&E), insulin (ab7842), glucagon (ab10988), or Ki67 (BD biosciences). The 
UMass Morphology Core performed the embedding, sectioning, and staining. To obtain 
β-cell mass, the ratio of β-cell area to total pancreas area was calculated and multiplied 
by the wet weight of the pancreas.  
Islet isolation and insulin secretion 
Islets were isolated from similarly weighted animals by ductal collagenase injection and 
Ficoll separation as previously described (314). Glucose-stimulated insulin secretion was 
measured using a perifusion system whereby 25 similarly shaped and sized islets were 
hand-selected using a microscope. Islets were incubated in 3mM glucose for 20 minutes 
then stimulated with a high concentration of glucose (20mM). Media was collected every 
1-3 minutes to assess the bi-phasic nature of insulin secretion. Secreted insulin in 
response to glucose was normalized to KCl secreted insulin.   
Statistics 
Results are described as the mean ± SEM. Significance was assessed using a two-tailed 
Student’s t-test.  
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Results and Discussion 
 
iMap4k4-KO mice display reduced insulin secretion 
Inducible systemic Map4k4 depletion (iMap4k4-KO) improves obesity-induced insulin 
resistance without altering glucose clearance (Chapter II). We hypothesized that reduced 
insulin secretion in iMap4k4-KO mice may mask potential effects on glucose clearance. 
To assess whether Map4k4 regulates insulin secretion, we collected plasma of HFD-fed 
tamoxifen-injected Map4k4flox/flox (control) and Map4k4-flox/flox-UBC-cre ERT2 
(iMap4k4-KO) mice after an overnight fast as well as 30 minutes after an intraperitoneal 
(IP) glucose injection. As predicted, an exogenous glucose surge promotes insulin 
secretion as assessed by increased circulating insulin levels 30 minutes after the glucose 
injection (Figure AI-1, A). iMap4k4-KO mice, however, displayed reduced insulin levels 
both basally and after glucose injection (Figure AI-1, A). These results suggest that 
iMap4k4-KO mice have reduced circulating insulin levels either due to altered insulin 
secretion or enhanced insulin turnover. Because proinsulin is packaged into vesicles 
before the connecting peptide (C-peptide) is removed, measurements of circulating C-
peptide levels are a direct measure of insulin secretion (315). Using the same conditions, 
we measured circulating C-peptide levels before and 30 minutes after a glucose injection, 
and observed that iMap4k4-KO mice displayed lower C-peptide levels (Figure AI-1, B). 
These data suggest Map4k4 depletion disrupts insulin secretion. We also measured 
circulating glucagon levels and detected no statistical differences between groups; thus, 
altered secretory effects are β-cell specific (Figure AI-1, C.). To assess whether the 
altered insulin secretion was mediated by a cell-autonomous effect or merely a result of 
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enhanced peripheral insulin sensitivity, we isolated islets from HFD-fed control and 
iMap4k4-KO mice and performed glucose-stimulated insulin secretion experiments 
(GSIS). Using a perifusion model, media was collected every few minutes and insulin 
secretion was measured either basally (3mM glucose) or with the addition of 20mM 
glucose or 20mM KCl. As expected, increasing glucose concentrations enhances insulin 
secretion in a biphasic manner, with the 1st wave of insulin secretion occurring 
approximately 5 minutes after the glucose surge and the 2nd wave of insulin secretion 
occurring 30 minutes after initial glucose surge. Interestingly, iMap4k4-KO mice 
displayed a significant reduction in the 1st wave of insulin secretion (Figure AI-1, D-E). 
We confirmed Map4k4 expression was significantly depleted in islets from iMap4k4-KO 
mice with a concomitant trend to reduced Insulin-1 and Insulin-2 gene expression (Figure 
AI-1, F). Consistent with a role of Map4k4 affecting in β-cell function, gene expression 
analysis of islet specification genes including Pancreatic and duodenal homeobox 1 (Pdx-
1), v-maf musculoaponeurotic fibrosarcoma oncogene family, protein A (MafA), and v-
maf musculoaponeurotic fibrosarcoma oncogene family, protein B (MafB) were 
significantly decreased in HFD-fed iMap4k4-KO islets (Figure AI-1, G). These results 
suggest that Map4k4 promotes obesity-induced hyperinsulinemia. 
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Figure AI-1. Map4k4 promotes HFD-induced hyperinsulinemia. 
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Figure AI-1. Map4k4 promotes HFD-induced hyperinsulinemia. (A-G) Both control 
and iMap4k4-KO mice were fed a high-fat diet for 16wks. (A) Fasting Insulin levels 
before and 30 minutes after glucose injection (* P<0.05, # P<0.0005, N=6-10). (B) 
Fasting C-peptide levels before and 30 minutes after glucose injection (* P<0.05, ** 
P<0.005, N=6-7). (C) Circulating fasting glucagon levels (N=6-8). (D-E) Glucose-
stimulated insulin secretion performed in isolated islets as described in Materials and 
Methods. D. Islets were incubated in 3mM glucose then stimulated with 20mM glucose 
was administered at 30 minutes KCl was administered at 65 minutes. E. Higher 
magnification of data within box from D (*; p<0.05, N=4). (F-G) Relative gene 
expression in isolated islets. Results represent the mean ± SEM (* P < 0.05 N=10). 
 
  102 
iMap4k4-KO mice display normal islet morphology with a concomitant reduction in 
islet mass 
To assess whether islet morphology was altered in iMap4k4-KO mice, leading to changes 
in insulin secretion, we isolated whole pancreas from HFD-fed control and iMap4k4-KO 
mice and determined islet morphology using immunofluorescent stains for β-cells 
(insulin) and α-cells (glucagon) (Figure AI-2, A). Although iMap4k4-KO mice display 
reduced insulin secretion, islet size and shape were similar between groups (Figure AI-2, 
A). Despite normal islet morphology, however, histological examination of the entire 
pancreas revealed a significant reduction in islet mass and number (Figure AI-2, B-C). 
Because obesity-induced insulin resistance is associated with an increase in β-cell 
number and mass that is partly mediated by enhanced β-cell proliferation (313), we 
measured β-cell proliferation rates using immunofluorescent stains for β-cells (insulin) 
and proliferating cells (Ki67) (Figure AI-2, D-E). HFD-fed iMap4k4-KO mice displayed 
a significant reduction in proliferation rates compared to control mice, consistent with a 
reduction in islet number and mass. These results suggest Map4k4 promotes HFD-
induced β-cell expansion by regulating β-cell proliferation. 
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Figure AI-2. Map4k4 depletion attenuates β-cell expansion.
Figure AI-2. Map4k4 depletion attenuates β-cell expansion. (A-E) Both control and 
iMap4k4-KO mice were fed a HFD for 16 wks. (A) Representative images of islets 
doubled stained with insulin (red) and glucagon (green). (B) Representative images of 
H&E stained pancreata. (C) β-cell mass quantification. The ratio of β-cell area to total 
pancreas was calculated and multiplied by wet weight of pancreas (* P<0.05, N=9-12).  
(D) Representative images of islets doubled stained for insulin (red) and Ki67 (green). 
(E) β-cell proliferation was determined by counting the number of Ki67 positive β-cells 
divided by the total number of β-cells. Results represent the mean ± SEM (* P < 0.05, 
N=4-5). 
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These results suggest Map4k4 may have dual pancreatic functions, promoting insulin 
secretion and β-cell expansion. First, Map4k4 is a positive regulator of insulin secretion; 
specifically Map4k4 depletion disrupts the 1st wave of insulin release. Insulin is released 
in a biphasic manner, with the 1st wave of insulin secretion occurring 5 minutes after 
glucose surge and the 2nd wave occurring 30 minutes after initial glucose surge. During 
the 1st wave of insulin secretion, glucose is metabolized, increasing the ATP:ADP ratio, 
which causes a closure of KATP channels (82). KATP channels closure causes a 
depolarization of the plasma membrane and opening of voltage-activated Ca2+ channels, 
allowing Ca2+ influx, and insulin vesicle exocytosis (82). Fewer mechanistic details are 
known about the 2nd wave of insulin secretion; however, it is hypothesized to be 
independent of KATP channels (84). Interestingly, previous studies suggest Map4k4 
directly binds and phosphorylates the Na+-H+ exchanger (Nhe1) (316). Nhe1 is a plasma 
membrane ion exchanger involved in regulation of intracellular pH (317). Nhe1 is highly 
expressed in β-cells and protects from intracellular acidification (317). Although Nhe1 is 
not causally involved in insulin secretion, suppression of Nhe1 augments insulin 
secretion via cytosolic acidification, closure of KATP channels, and insulin (318). We 
hypothesize that Map4k4 inhibits Nhe1 via direct phosphorylation; thus, Map4k4 
depletion enhances Nhe1 activity and results in less β-cell cytosolic acidification and less 
insulin release. Second, Map4k4 promotes β-cell expansion by regulating β-cell 
proliferation. HFD-fed iMap4k4-KO mice displayed reduced β-cell proliferation, which 
was associated with a reduction β-cell number and mass. These results suggest Map4k4 
  105 
may be a novel therapeutic target improving peripheral insulin resistance and lowering 
hyperinsulinemic conditions that occur in obesity-induced insulin resistance.  
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